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Abstract 
The p53 tumor suppressor protein is upregulated in response to DNA damage 
and other stress signals.  The upregulation of p53 involves freeing it from 
negative regulation imposed by Mdm2 and MdmX (Mdm4).  Accumulating 
evidence indicates that phosphorylation of Mdm proteins by different stress-
activated kinases such as ATM or c-Abl significantly impacts p53 functions.  We 
have previously shown that ATM phosphorylation of Mdm2 Ser394 is required for 
robust p53 stabilization and activation following DNA damage.   
This dissertation describes in vivo examination of the mechanism by which 
Mdm2 Ser394 phosphorylation impacts p53 activities and its contribution to 
suppression of oncogene and DNA damage-induced tumors.  We determine that 
phosphorylation of Mdm2 Ser394 regulates p53 activity by modulating Mdm2 
stability and paradoxically delays Myc-driven lymphomagenesis while increasing 
lymphomagenesis in sub-lethally irradiated mice. 
c-Abl phosphorylates the residue neighboring Mdm2 Ser394, Mdm2 Tyr393.  
This dissertation describes the generation of a novel Mdm2Y393F mutant mouse to 
determine if c-Abl phosphorylation of Mdm2 regulates p53-mediated DNA 
damage responses or tumor suppression in vivo.  Mdm2Y393F mice develop 
accelerated spontaneous and oncogene-induced tumors, yet display no defects 
in p53 stabilization and activity following acute genotoxic stress.  Furthermore, 
the effects of these phosphorylation events on p53 regulation are not additive, as 
Mdm2Y393F/S394A mice and Mdm2S394A mice display similar phenotypes. 
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The studies presented herein further our understanding of the mechanisms by 
which DNA damage-associated kinases stabilize and activate p53, and influence 
p53-dependent responses and tumor suppression.  A better understanding of the 
in vivo effects of Mdm2 phosphorylation may facilitate the development of novel 
therapeutics capable of stimulating p53 anti-tumor activity or alleviating p53-
dependent toxicities in non-malignant tissues.			 	
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CHAPTER I 
Introduction 
 
p53 
The p53 protein was first identified in 1979, through studies examining the 
transforming ability of the simian virus 40 (SV40) tumor virus.  p53 was found to 
be bound by the SV40 large T antigen, and p53 protein levels were elevated in a 
number of SV40-transformed cell lines (Melero et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979; Chang et al., 1979; Kress et al., 1979).  Several 
groups proceeded to clone the p53 cDNA (Pennica et al., 1984; Bienz et al., 
1984; Parada et al., 1984; Jenkins et al., 1984), and ensuing studies with several 
of these clones demonstrated that p53 cooperated with Ha-Ras in transforming 
primary rat cells in culture (Eliyahu et al., 1984; Parada et al., 1984; Jenkins et 
al., 1984).  Accordingly, p53 was initially perceived to be oncogenic.  However, 
further experimentation determined that the p53 sequences that facilitated 
transformation included mutations, and that those mutations were responsible for 
the cooperation with Ras (Finlay et al., 1988; Hinds et al., 1989).  Moreover, 
transformation studies using the wild-type (WT) p53 sequence showed that p53 
actually blocked the ability of Myc or E1A plus Ras to transform cells (Finlay et 
al., 1989; Eliyahu et al., 1989).  These results, coupled with accumulated 
evidence of p53 mutation in tumors from a Friend leukemia virus-driven mouse 
tumor model (Mowat et al., 1985; Chow et al., 1987; Munroe et al., 1988; Ben 
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David et al., 1988), as well as the first evidence of p53 mutation contributing to 
human cancer (Baker et al., 1989), ultimately led to a reversal of the field’s 
interpretation of p53 and the recognition of p53 as a tumor suppressor.   
 
p53 structure and function 
Shortly after p53’s identification as a tumor suppressor, studies focused 
on the biochemical properties of p53 showed that it could bind DNA in a 
sequence-specific manner (Kern et al., 1991; El-Deiry et al., 1992; Funk et al., 
1992) and stimulate the expression of genes downstream of its binding site (Kern 
et al., 1992; Funk et al., 1992; Zambetti et al., 1992).  The 20 base pair p53 
consensus-binding sequence is comprised of two copies of the palindromic 10 
base pair sequence 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ separated by up to 13 
base pairs (El-Deiry et al., 1992; Funk et al., 1992).  The site-specific binding of 
p53 to DNA is dependent upon a central DNA-binding domain spanning residues 
102-292 (Pavletich et al., 1993; Bargonetti et al., 1993; Cho et al., 1994).  The 
majority of cancer-associated p53 mutations are missense mutations within this 
domain which ablate DNA binding.  Approximately 30% of these mutations occur 
at six residues (Arg175, Gly245, Arg248, Arg249, Arg273 and Arg282) known as 
‘hotspots’ (Vousden and Lu, 2002).  This emphasizes a critical role for p53 
transcriptional activities in tumor suppression, and follows with the observation 
that the sequence-specific DNA binding ability of various p53 mutants positively 
correlates with growth-suppressor activity (Pietenpol et al., 1994).  
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The highly acidic nature of the N-terminal region of p53 led to its early 
identification as the region of p53 containing its transcription activating domain 
(Fields and Jang, 1990; Raycroft et al., 1990).  Later studies confirmed that this 
region of p53 contains a pair of transcriptional activation domains (TADs), TAD1 
and TAD2, which span amino acid residues 1-40 and 40-60, respectively 
(Candau et al., 1997; Zhu et al., 1998; Venot et al., 1999).  These domains act to 
promote the transcription of p53 target genes by recruiting components of the 
basal transcriptional machinery (Lu and Levine, 1995; Thut et al., 1995; Di Lello 
et al., 2006), histone-modifying enzymes such as CREB-binding protein 
(p300/CBP) (Gu et al., 1997; Teufel et al., 2007), and coactivator complexes, 
such as STAGA and Mediator (Gamper and Roeder, 2008; Meyer et al., 2010).  
In addition to activating transcription, p53 can repress gene expression by 
binding to specific p53 response elements and recruiting co-repressors such as 
histone deacetylases and by obstructing binding sites for other transcriptional 
activators (Ho and Benchimol, 2003; Riley et al., 2008).  The N-terminus of p53 is 
also the site of a multitude of phosphorylation events by stress-responsive 
kinases, as well as binding by the negative regulators of p53, Mdm2 and MdmX 
(discussed below). 
Located between the N-terminal TADs and the central DNA binding 
domain is a proline-rich domain (PRD; residues 60-95).  This domain was 
originally proposed to participate in protein-protein interactions on the basis of 
the presence of PXXP motifs which create binding sites for Src homology 3 
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(SH3) domain-containing proteins (Walker and Levine, 1996).  The PRD has 
been implicated in the regulation of p53 activity through interaction with the 
histone acetyl transferase p300, promoting p53 acetylation (Dornan et al., 2003).  
The PRD has also been shown to modulate Mdm2-mediated degradation of p53 
(Berger et al., 2001).  This is attributed to the the prolyl isomerase Pin1 binding 
the PRD after stress and effecting a conformational change in p53 to reduce 
Mdm2 binding (Zheng et al., 2002; Zacchi et al., 2002).  Cells expressing p53 
lacking the PRD display increased colony formation (Walker and Levine, 1996) 
and reduced apoptosis in response to activated oncogenes as well as various 
DNA damage-inducing anti-neoplastic agents (Sakamuro et al., 1997; Roth et al., 
2000; Baptiste et al., 2002).  However, while complete deletion of this domain in 
mice disrupts p53 growth arrest and tumor-suppressor function, knock-in mice 
carrying proline-to-alanine point mutations in all PXXP motifs of this domain 
appear normal, suggesting that the contributions of this domain to p53 function 
may be largely structural (Toledo et al., 2006; Toledo et al., 2007). 
C-terminal to the DNA-binding domain is a tetramerization domain 
(residues 325-356) which directs p53 oligomerization and binding of its response 
elements as a tetramer (Stenger et al., 1992; Friedman et al., 1993; Pavletich et 
al., 1993).  Interestingly, the majority of p53 mutants retain an intact 
tetramerization domain, allowing mutant p53 proteins to assemble into tetramers 
along with wild-type p53 proteins.  As a result, mutant p53 can display a 
dominant-negative effect on p53 DNA binding and transactivation function 
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(Sturzbecher et al., 1992; Shaulian et al., 1992). 
Finally, the extreme C-terminus of p53 contains a basic, lysine-rich 
domain (residues 363-393).  This domain is proposed to regulate the DNA-
binding ability of p53 by altering its conformation, or sterically interfering with 
DNA binding (Luo et al., 2004; McKinney et al., 2004; Friedler et al., 2005).  This 
activity is linked to post-translational modification of the domain.  Six C-terminal 
lysines of p53 are acetylated by p300/CBP (Gu and Roeder, 1997), in a 
sequence dependent on phosphorylation of the same region by kinases such as 
protein kinase C and casein kinase II (Baudier et al., 1992; Hupp et al., 1992; 
Sakaguchi et al., 1998).  Accordingly, p53 acetylation levels are elevated in 
response to stress, promoting p53 activation (Sakaguchi et al., 1998; Ito et al., 
2001).  Importantly, these same lysine residues are principle sites of ubiquitin 
ligation by Mdm2 (Rodriguez et al., 2000; Nakamura et al., 2000), the primary 
regulator of p53 stability (discussed below).  Acetylation and ubiquitination are 
mutually exclusive modifications, and competition between these modifications is 
thought to regulate p53 stability and activity (Ito et al., 2001; Li et al., 2002b).  
Several other lysines located in the DNA binding and tetramerization domains of 
p53 are also targets of acetylation (Tang et al., 2008).  Acetylation of these 
residues is reported to influence the relative activation of different p53 target 
genes (Meek, 2015). 
Since the identification of p53 as a transcription factor, a multitude of p53-
responsive genes have been identified, implicating p53 in the control of 
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numerous cellular responses to a wide range of stresses, such as various forms 
of DNA damage, ribosomal stress, activated oncogenes and hypoxia.  Among 
the first p53-responsive genes to be discovered was CDKN1A, encoding the 
cyclin dependent kinase inhibitor p21 (WAF1/CIP1) (El-Deiry et al., 1993), which 
governs cell cycle arrest in response to DNA damage (Deng et al., 1995; 
Brugarolas et al., 1995) and mediates cellular senescence (Noda et al., 1994; 
Fang et al., 1999; Wang et al., 1999).  Additional p53-targets involved in cell 
cycle arrest and senescence include the growth arrest-related genes Gadd45 
(growth-arrest and DNA damage-inducible protein 45) (Kastan et al., 1992), 14-3-
3-σ (Hermeking et al., 1997), Reprimo (Ohki et al., 2000), and senescence 
associated PAI-1 (plasminogen activator inhibitor-1) (Kortlever et al., 2006).  p53 
is also capable of transactivating the expression of several genes involved in 
apoptosis, such as the Bcl-2 family members Bax (Miyashita and Reed, 1995), 
Noxa (Oda et al., 2000), and Puma (Nakano and Vousden, 2001; Yu et al., 
2001).  p53-targets involved in DNA repair include Ercc5 (Excision repair cross-
complementing rodent repair deficiency complementation group 5) and Mgmt (O 
(6)-methylguanine-DNA methyltransferase) (Valente et al., 2013).  p53-targets 
involved in metabolic processes and regulation of oxidative stress include TIGAR 
(TP53-induced glycolysis regulator) (Bensaad et al., 2006), Sco2 (synthesis of 
cytochrome c oxidase) (Matoba et al., 2006), Gls2 (Glutaminase 2) (Hu et al., 
2010; Suzuki et al., 2010), Aldh4 (aldehyde dehydrogenase 4) (Yoon et al., 2004) 
and the Sestrins, Sesn1 (Sestrin-1/PA26) and Sesn2 (Sestrin-2/Hi95) (Velasco-
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Miguel et al., 1999; Peeters et al., 2003; Budanov et al., 2002; Bodanov et al., 
2004).  Novel p53-dependent target genes encoding proteins involved in a 
growing number of signaling pathways and cellular functions, are constantly 
being described.  The relative contribution of these pathways and functions to the 
tumor suppressive effect of p53 is still being elucidated (Brady et al., 2011; Li et 
al., 2012; Jiang et al., 2015). 
 
p53 tumor suppression  
Proper coordination of p53-responsive gene expression provides a crucial 
barrier to tumor development.  This is evidenced by the fact that more than 50% 
of human cancers harbor mutations in p53 (Levine, 1997; Soussi and Beroud, 
2001).  Moreover, in cancers in which p53 is wild-type, p53 function is frequently 
compromised through mutations of associated positive regulators, or 
amplification of negative regulators of p53 (Levine, 1997).  A number of p53-null 
mouse models have been developed and characterized (Donehower et al., 1992; 
Clarke et al., 1993; Jacks et al., 1994).  While it was initially reported that p53 /  
mice developed normally both prenatally and postnatally, it was subsequently 
shown that a primarily female subset of p53 /  mice die in utero due to 
exencephaly (Sah et al., 1995; Armstrong et al., 1995).  In all cases, mice 
homozygous for the null allele rapidly developed spontaneous tumors, with 
similar spectrums and latencies (Donehower et al., 1992; Purdie et al., 1994; 
Jacks et al., 1994).  All p53 /  mice develop tumors by 10 months of age, with a 
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mean time to tumorigenesis of approximately 4.5 months.  These tumors are 
primarily lymphomas (~70-80%, largely T-cell in origin), with some incidence of 
sarcomas and other tumor types.  p53+/  mice develop tumors later than p53 /  
mice, with the earliest tumor presentation around 12 months of age (Harvey et 
al., 1993a; Purdie et al., 1994; Jacks et al., 1994).  The majority of p53+/  mice 
(~95%) develop tumors by 24 months of age, with a mean time to tumorigenesis 
of approximately 17 months.  These animals present with lymphomas (primarily 
of B cell origin), osteosarcomas, soft-tissue sarcomas and a range of carcinomas 
(Donehower and Lozano, 2009).  Interestingly, one study observed that while the 
remaining wild-type p53 allele is deleted in approximately half of p53+/  tumors, 
supporting the Knudson hypothesis, the other half retain a functional wild-type 
allele (Venkatachalam et al., 1998).  While this may suggest that perturbation of 
other members of the p53 signaling axis accounts for functional loss of p53 in 
these tumors, it has been suggested that in certain contexts p53 may be 
haploinsufficient, and that a reduction in p53 dosage is sufficient to increase the 
susceptibility of p53+/  cells to tumorigenesis (Venkatachalam et al., 2001). 
In agreement with the early observations that p53 impaired the ability the 
ability of oncogenes to transform cells (Finlay et al., 1989; Eliyahu et al., 1989), 
numerous studies have shown that combining the p53-null allele with mouse 
models of cancer, such as those driven by PTEN deficiency, activated 
BRAFV600E, or Myc overexpression, leads to accelerated tumor development 
(Chen et al., 2005b; Dankort et al., 2007; Eischen et al., 1999).  Early in vitro 
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studies aimed at identifying the mechanism by which p53 impaired tumor 
formation identified p53 as a regulator of cell growth and senescence, as well as 
apoptosis.  Overexpression of p53 was shown to inhibit the growth of a number 
of human cancer cell lines (Baker et al., 1990; Diller et al., 1990; Chen et al., 
1990).  Similar results were observed in cells expressing a temperature-sensitive 
p53 mutant (p53val135) at the wild-type-permissive temperature, with growth 
arrest reported to occur primarily in G1 (but also G2/M) (Michalovitz et al., 1990; 
Martinez et al., 1991).  Additionally, biochemical experiments identified p53 as a 
substrate of cyclin-dependent kinase 1 (CDK1) (Bischoff et al., 1990; 
Sturzbecher et al., 1990).   
An early indication of the role for p53 in senescence came from the 
observation that p53 mutation was a common event in the spontaneous 
immortalization of MEFs (Harvey and Levine, 1991).  This was further supported 
by studies showing that p53 /  fibroblasts are more readily immortalized in culture 
(Harvey et al., 1993b; Tsukada et al., 1993), that mutant p53 extends the 
proliferative life span of fibroblasts (Bond et al., 1994), and that p53 expression 
(Kulju and Lehman, 1995) and transactivation activity (Bond et al., 1996, Atadja 
et al., 1995) increase as cells approach senescence.  Reintroduction of wild-type 
p53 triggers rapid senescence in certain human tumor cells lacking functional p53 
(Sugrue et al., 1997), and p53 is essential for oncogene-induced senescence in 
cells overexpressing Ras, E2F1 and constitutively active b-catenin (Serrano et 
al., 1997; Dimri et al., 2000; Damalas et al., 2001).  A role for p53-dependent 
		 	 	 10	
senescence in tumor suppression in mice has been suggested by a study in 
which mice expressing a mutant p53 protein (p53R172P), defective for apoptosis 
but retaining growth arrest capabilities, displayed delayed Eµ-myc-driven B cell 
lymphomagenesis compared to mice heterozygous for p53 (Post et al., 2010).  
Lymphomas from p53R172P expressing mice displayed increased levels of 
senescence-associated b-galactosidase activity relative to mice heterozygous for 
p53.   
The influence of p53 on growth arrest and senescence has been largely 
attributed to p21.  p21 protein levels increase in normal fibroblasts as they 
approach senescence (Noda et al., 1994) and p21 /  cells display reduced growth 
arrest in response to DNA damage (Deng et al., 1995; Brugarolas et al., 1995).   
Furthermore, tumor cell lines lacking functional p53 failed to arrest in response to 
forced expression of p53 when the p21 gene was disrupted (Polyak et al., 1996), 
and induced expression of p21 promotes senescence in tumor cells lacking 
functional p53 (Fang et al., 1999; Wang et al., 1999).   
Induced expression of p53 has also been shown to stimulate apoptosis in 
vitro in various human cancer cell lines (Yonish-Rouach et al., 1991; Shaw et al., 
1992; Yang et al., 1995; Liu et al., 1995).  By expressing p53, either under the 
control of a metal ion-inducible rat MT promoter (Shaw et al., 1992), or through 
adenoviral delivery (Yang et al., 1995; Liu et al., 1995), several of these groups 
further showed that p53 expression in tumor cells inhibits tumor formation in 
nude mice, and that established tumor xenografts undergo regression and 
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display histological features of apoptosis when p53 expression is induced.  
Studies in primary murine cells have shown p53 accumulation and stabilization, 
along with increased apoptosis, in response to adenovirus E1A expression (Lowe 
and Ruley, 1993), as well as induction of apoptosis in cells co-expressing E1A 
and the temperature-sensitive p53val135 mutant at the wild-type-permissive 
temperature (Debbas and White, 1993).  A subsequent study using p53 /  MEFs 
confirmed the p53-dependence of E1A-induced apoptosis, and demonstrated 
that reduced apoptosis increases the tumorigenic potential of cells in nude mice 
(Lowe, et al., 1994).  Similar results to those observed with E1A in vitro were 
observed in cells expressing c-Myc fused to the hormone binding domain of the 
human estrogen receptor (c-MycER).  Activation of c-Myc in wild-type MEFs 
induces apoptosis not observed in similarly transfected p53 /  MEFs (Hermeking 
and Eick, 1994; Wagner et al., 1994).   
Additional results implicating p53-dependent apoptosis in tumor 
suppression have been reported from a number of studies in mice.  p53-
dependent apoptosis has been shown to suppress Eµ-myc-driven B cell 
lymphomagenesis (Schmitt et al., 1999), E2F1 driven skin carcinomas (Pierce et 
al., 1998), and brain tumorigenesis driven by a mutant SV40 T antigen (non p53-
binding TgT121) (Symonds, et al., 1994).  Furthermore, the development of TgT121 
and Eµ-myc-driven tumors is accelerated in mice null for the p53-responsive 
apoptotic gene Bax (Yin et al., 1997; Eischen et al., 2001).  A similar acceleration 
of Eµ-myc-driven tumors has been described in mice null for the p53-responsive 
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apoptotic gene Puma (Hemann et al., 2004; Garrison et al., 2008; Michalak et al., 
2009). 
The aforementioned results detailing the contributions of p53-dependent 
growth arrest, senescence and apoptosis to tumor suppression in various tissues 
and cell-types, highlight the importance of these tumor-suppressive mechanisms.  
However, the relative contribution of these mechanisms is likely to be tissue- or 
cell-type-dependent.  This is exemplified by a series of studies in which p53 
reactivation in established tumors resulted in apoptosis in lymphomas and 
senescence in sarcomas, respectively (Martins et al., 2006; Xue, et al., 2007; 
Ventura, et al., 2007).  More recently, a number of studies have questioned the 
influence of cell cycle arrest, senescence and apoptosis in tumor suppression, 
and implicated additional p53-dependent mechanisms in impairing tumor growth.  
Gu and colleagues have described a knock-in mouse in which three p53 
acetylation sites in the p53 DNA-binding domain were mutated to arginine 
(p533KR mice) (Li et al., 2012).  p533KR mice and cells fail to transactivate the 
majority of p53 target genes, and induce growth arrest or apoptosis.  However, 
these mice do not develop cancer, suggesting that tumor suppression by p53 
may occur independently of growth arrest or apoptosis.  It is proposed that as 
these animals retain the ability to transactivate the metabolic targets Gls2 and 
TIGAR, p53 may display tumor suppressive activity through the regulation of 
energy metabolism and reactive oxygen species (ROS) levels (Li et al., 2012).  
Similar findings have been reported using, triple knock-out mice deficient for p21, 
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Puma, and Noxa (p21 / puma / noxa /  mice) (Valente, et al., 2013).  These mice 
are profoundly resistant to DNA damage-associated apoptosis and growth arrest, 
and largely (but not entirely) resistant to p53-dependent senescence, yet do not 
develop spontaneous tumors.  These authors noted that induction of p53 target 
genes involved in DNA repair was unperturbed in p21 / puma / noxa /  mice, and 
propose that coordination of DNA repair is an essential tumor suppressive 
activity of p53.  More recently, Gu and colleagues have identified the ability of 
p53 to transcriptionally repress the cysteine/glutamate antiporter SLC7A11 and 
induce ferroptosis (an iron-dependent mechanism of non-apoptotic cell death 
(Dixon, et al., 2012)) in response to reactive oxygen species as another 
mechanism by which p533KR mice may suppress tumorigenesis (Jiang, et al., 
2015).   
 
p53 responses to DNA damage 
Following the identification of p53 as a tumor suppressor protein, and in 
concert with the aforementioned studies elucidating the tumor suppressive 
activities of p53, a series of studies showed that p53 levels and activity increased 
in response to DNA damage.  Treatment of cells with DNA damaging agents 
such as ultraviolet light (UV), ionizing radiation (IR), and numerous cancer 
therapeutic and/or DNA damage-inducing compounds such as 
diamminedichloroplatinum (cisplatin), mitomycin C, etoposide, hydroxyurea (HU), 
methyl methanesulfonate (MMS) and actinomycin D results in increased p53 
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protein levels and associated cell cycle arrest (Maltzman and Czyzyk, 1984; 
Kastan, et al., 1991; Fritsche et al., 1993; Zhan et al., 1993).  Tumor cells lacking 
p53 fail to induce growth arrest following IR, a result that can be reversed by 
transfection with wild-type p53 (Kastan et al., 1991; Kuerbitz et al., 1992).  
Furthermore, p53 /  MEFs are resistant to oncogene-sensitized apoptosis in 
response to serum withdrawal or a variety of genotoxic agents (Lowe et al., 
1993a; Lowe et al., 1994).  Analyses of p53 /  mice determined that p53 governs 
IR-induced apoptosis in both thymocytes (Lowe et al., 1993b; Clarke et al., 1993; 
Lotem and Sachs, 1993) and epithelial stem cells of the small intestine (Merritt et 
al., 1994).  Further studies have identified additional radiosensitive cell 
populations in the spleen, bone marrow, and hair follicles (Komarova et al., 
2000).  
An early indication of the signaling pathways governing the p53 response 
to DNA damage came from a study that showed cells from patients with ataxia-
telangiectasia (an autosomal recessive disorder resulting in neuronal 
degeneration, sensitivity to ionizing radiation, premature ageing, increased 
incidence of cancer and other pathologies) do not display increased p53 levels 
and activity following IR exposure (Kastan et al., 1992).  Mice null for ATM 
(ataxia telangiectasia mutated), the gene responsible for ataxia-telangiectasia, 
are extremely sensitive to IR-induced lethality, and cells and tissues from these 
mice show profound defects in DNA damage-induced growth arrest and 
apoptosis (Barlow et al., 1996; Elson et al., 1996; Xu and Baltimore, 1996; 
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Herzog et al., 1998).  Similar to AT patient cells, p53 is not stabilized in ATM /  
MEFs or thymocytes following IR (Xu and Baltimore, 1996; Gurley and Kemp, 
2007).  Furthermore, these animals succumb to T-cell lymphomas by 6 months of 
age (Barlow et al., 1996; Elson et al., 1996).  Research aimed at identifying the 
mechanism by which ATM leads to p53 stabilization is discussed below. 
 
Mdm proteins regulate p53 
Mdm2 
The chief negative regulator of p53 stabilization and activity is widely 
considered to be the Mdm2 oncoprotein.  The Mdm2 (murine double minute 2) 
gene was initially identified as an amplified DNA sequence associated with 
double minutes (small, acentromeric extrachromosomal nuclear bodies) present 
in a spontaneously immortalized mouse 3T3 cell line and shown to originate from 
mouse chromosome 10 (Cahilly-Snyder et al., 1987).  The Mdm2 protein was 
initially observed as a cellular protein of approximately 90 kDa which co-
immunoprecipitated with p53 from rat embryo fibroblasts (Hinds et al., 1990).  
This protein was subsequently purified from cells overexpressing p53 and 
identified by sequence homology as the product of the predicted open reading 
frame of Mdm2 (Momand et al., 1992).  In this same study, co-expression of 
Mdm2 with p53 was shown to inhibit the ability of p53 to transactivate a reporter 
plasmid.  These findings closely coincided with the identification of Mdm2 as an 
oncogene.  Mdm2 overexpression is capable of conferring tumorigenicity on cells 
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(Fakharzadeh et al., 1991), and Mdm2 is amplified in a significant fraction (~30%) 
of soft tissue sarcomas (Oliner et al., 1992; Leach et al., 1993; Cordon-Cardo et 
al., 1994).  Further studies have identified Mdm2 amplification in a variety of 
other tumor types, including breast carcinomas (Sheikh et al., 1993), 
glioblastomas and astrocytomas (Reifenberger et al., 1993), myeloid neoplasms 
(Bueso-Ramos et al., 1993), B cell lymphomas (Watanabe et al., 1994) and oral 
carcinomas (Matsumura et al., 1996). 
Shortly after the identification of Mdm2’s interaction with p53, mapping of 
the p53 and Mdm2 interaction domains, by yeast two-hybrid and co-
immunoprecipitation experiments, determined that the N-terminus of Mdm2 
bound to the transactivation domain of p53 (Oliner et al., 1993; Chen et al., 
1993).  These same groups further showed that this interaction inhibited the 
transactivation ability of p53 in reporter assays.  Accordingly, Mdm2 
overexpression cooperates with Ras in transforming primary cell lines, despite 
the presence of wild-type p53 (Finlay, 1993).  Mdm2 overexpression also inhibits 
p53-dependent growth arrest and apoptosis in various cell lines, in response to 
either DNA damage or activated oncogenes (Chen et al., 1994; Haupt et al., 
1996; Chen et al., 1996).  It has since been determined that the central acidic 
domain of Mdm2 also interacts with p53, though with a weaker affinity than that 
observed with the N-terminal.  This interaction is thought to further stabilize the 
Mdm2-p53 interaction (Yu et al., 2006).   
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It was subsequently shown that in addition to inhibiting the transactivation 
ability of p53, Mdm2 promotes the proteasomal degradation of p53 (Haupt et al., 
1997; Kubbutat et al., 1997).  Mdm2 functions as an E3 ubiquitin ligase capable 
of directing p53 polyubiquitination (Honda et al., 1997).  This E3 activity of Mdm2 
is dependent on its C-terminal RING finger domain (Fang et al., 2000).  The 
Mdm2 RING finger has also been shown to promote the nuclear export of p53 by 
directing its monoubiquitination (Boyd et al., 2000; Geyer et al., 2000; Lohrum et 
al., 2001; Gu et al., 2001).  It is proposed that low levels of Mdm2 activity induce 
monoubiquitination and nuclear export of p53, whereas high levels promote 
polyubiquitination and nuclear degradation of p53 (Li et al., 2003).  As discussed 
above, the principle sites of ubiquitin ligation by Mdm2 are a series of C-terminal 
lysines also targeted by acetylation, creating one of many layers of regulation of 
p53 stability and activity (Rodriguez et al., 2000; Nakamura et al., 2000; Ito et al., 
2001; Li et al., 2002b).  Notably, the Mdm2 gene is itself a target of the p53 
transcription factor (Wu et al., 1993; Juven et al., 1993).  As p53 becomes 
stabilized and active, it increases the levels of its own negative regulator Mdm2, 
forming an autoregulatory feedback loop that returns p53 protein and activity to 
basal levels.  Furthermore, Mdm2 has also been shown to be capable of 
directing its own degradation (Fang et al., 2000; Honda and Yasuda, 2000). 
The crucial role of Mdm2 in regulating p53 activity is illustrated by the p53-
dependent lethality of Mdm2-null mice during early embryogenesis.  Mdm2 /  
mice display embryonic lethality at E5.5-6.5 of early development (Montes de 
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Oca Luna et al., 1995; Jones et al., 1995).  This loss of viability is due to 
unregulated p53 activity in developing embryos, as crossing these mice with the 
p53-null allele completely rescues Mdm2-null mice (Montes de Oca Luna et al., 
1995; Jones et al., 1995).  Mice null for both Mdm2 and p53 develop 
spontaneous tumors of similar incidence and spectrum as p53-null mice (Jones 
et al., 1996).  Furthermore, primary p53-null and Mdm2/p53 double-null cells 
display similar growth characteristics in culture and are indistinguishable in their 
response to genotoxic agents (Jones et al., 1996).  These results highlight 
regulation of p53 as the primary role of Mdm2.  Mdm2+/  mice display delayed 
Myc-driven lymphomagenesis (Alt et al., 2003), an observation ascribed to 
increased p53-dependent apoptosis in Myc expressing B cells.  In another study 
employing a hypomorphic Mdm2 allele, mice expressing reduced levels of Mdm2 
displayed p53-dependent sensitivity to radiation-induced lethality and apoptosis 
in lymphopoietic tissues (Mendrysa et al., 2003).  Thus, perturbations in the 
levels of Mdm2 can significantly impact p53 responses to oncogenes and DNA 
damage.  
In contrast with Mdm2-null mice, mice overexpressing an Mdm2 transgene 
are viable, but succumb to spontaneous tumors (Jones et al., 1998).  The rate of 
tumorigenesis in Mdm2-transgenic mice is slower than that observed in p53 /  
mice, with 50% of Mdm2-transgenics developing tumors by 19 months (as 
opposed to 4.5 months for p53 /  mice).  It is suggested that this may be due to 
the relatively modest levels of Mdm2 overexpression (approximately 4 fold) 
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present in the Mdm2-transgenics.  Mdm2-transgenics present with a large 
percentage of lymphomas, similar to what is observed in p53 /  mice, as well as a 
large number of sarcomas (predominantly hemangiosarcomas).  Notably, while 
the Mdm2-transgene does not accelerate spontaneous tumorigenesis in p53 /  
mice, it does increase the number of sarcomas observed (in addition to the 
previously observed tumor spectrum and incidence), suggesting a possible p53-
independent contribution of Mdm2 overexpression to tumorigenesis.  Mdm2 
overexpressing mice also display accelerated Myc-driven lymphomagenesis 
(Wang et al., 2008).  This same study showed that elevated levels of Mdm2 
resulted in reduced p53 protein levels and activity in B cells, and reduced B cell 
apoptosis following IR.     
 
MdmX 
Similar to Mdm2, the related protein MdmX (Mdm4) is also capable of 
binding p53 and inhibiting p53 transactivation of target genes (Shvarts et al., 
1996; Shvarts et al., 1997).  MdmX and Mdm2 share 34% protein homology and 
contain highly homologous p53-binding, acidic, zinc finger, and RING finger 
domains (Shvarts et al., 1996).  As with Mdm2, the MdmX gene is amplified or 
overexpressed in a variety of tumor types, including brain and breast cancers, 
soft tissue sarcomas, retinoblastoma and melanoma (Riemenschneider et al., 
2003; Danovi et al., 2004; Bartel et al., 2005; Laurie et al., 2006; Gembarska et 
al., 2012).  However, unlike Mdm2, MdmX does not possess the ability to directly 
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ubiquitinate p53 (Jackson and Berberich, 2000; Stad et al., 2000).   
Mice null for MdmX display a similar p53-dependent embryonic lethality as 
observed in Mdm2 /  mice, albeit slightly later in development (E9.5-10.5), and 
are rescued by deletion of p53 (Parant et al., 2001; Migliorini et al., 2002; Finch 
et al., 2002).  Notably, the lethality in MdmX /  embryos appears to be 
predominantly associated with a lack of proliferation, as opposed to aberrant 
apoptosis (as reported for Mdm2 /  embryos (de Rozieres et al., 2000)).  
Accordingly, a subsequent study revealed that co-deletion of p21 can 
significantly delay the embryonic lethality of MdmX-null mice (Steinman et al., 
2004).  MdmX+/  MEFs display a decreased growth rate and increased levels of 
UV-induced apoptosis (Finch et al., 2002).  This is attributed to elevated protein 
levels of p53 and several p53 target gene products including p21 and Bax.  As 
observed with mice heterozygous for Mdm2, MdmX+/  cells and mice display 
decreased oncogene-driven transformation and Eµ-myc-driven 
lymphomagenesis, respectively (Terzian et al., 2007).  Furthermore, MdmX+/  
mice are similarly sensitized to radiation induced lethality as observed with 
Mdm2+/  mice (Terzian et al., 2007). 
Mdm2 and MdmX have been shown to interact via their C-terminal RING 
domains (Tanimura et al., 1999; Sharp et al., 1999).  This interaction was initially 
reported to stabilize both Mdm2 (Tanimura et al., 1999; Sharp et al., 1999; Stad 
et al., 2000) and p53 (Sharp et al., 1999; Jackson and Berberich, 2000; Stad et 
al., 2000).  However, it was later shown that the observed stabilization of p53 by 
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MdmX was likely due to exceedingly high levels of MdmX generated in 
transfection-based studies, and that stabilization of Mdm2 by heterodimerization 
with MdmX actually increases the ability of Mdm2 to degrade p53 (Gu et al., 
2002; Linares et al., 2003; Kawai et al., 2007; Wang et al., 2011b).  Notably, the 
turnover of MdmX is mediated by Mdm2 (Pan and Chen, 2003; de Graaf et al., 
2003; Kawai et al., 2003). 
Recently, a series of Mdm2 and MdmX knock-in mouse models have been 
generated that display altered Mdm2-MdmX interactions and/or Mdm2 E3 ligase 
activity (Itahana et al., 2007; Pant et al., 2011; Huang et al., 2011; Tollini et al., 
2014).  Analyses of these models have revealed that Mdm2-MdmX interactions 
are crucial for inhibiting p53 activity during development and tissue homeostasis, 
whereas the E3 ligase function of Mdm2 is vital for regulating p53 protein levels 
and activity in cellular and organismal responses to DNA damage (Tollini et al., 
2014). 
 
p53 stabilization and activation in response to stress 
The inhibitory role of Mdm proteins on p53 protein stabilization and 
activities must be interrupted in order for p53 to become elevated and activated 
in response to DNA damage or other forms of stress. 
 
Oncogene-induced ARF-Mdm2 interaction 
An important mediator of oncogene-dependent activation of p53 is the 
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tumor suppressor protein p19ARF (p14ARF in humans).  Oncogenes including c-
Myc, Ras and E1A induce ARF and cause p53-dependent growth arrest and 
apoptosis (Zindy et al., 1998; de Stanchina et al., 1998; Palmeiro et al., 1998).  
ARF binds to Mdm2 and can block its ubiquitin ligase activity towards p53 
(Pomerantz et al., 1998; Zhang et al., 1998; Kamijo et al., 1998; Stott et al., 1998; 
Honda and Yasuda, 1999; Midgley et al., 2000) as well as sequester Mdm2 in 
the nucleolus (Weber et al., 1999; Tao and Levine, 1999).  This facilitates p53 
protein stabilization and activation in order to limit the transformative effects of 
aberrant oncogene activity. 
 
DNA damage-induced modifications of p53 
The cellular response to DNA damage is primarily governed by the PI3K-
related serine/threonine kinases (PIKKs) ATM and ATR (ataxia telangectasia and 
Rad3-related protein).  ATM is activated by DNA damaging agents that create 
double-strand breaks (DSBs), while ATR is activated following recruitment to 
ssDNA regions.  The related protein DNA-PKcs (DNA-dependent protein kinase 
catalytic subunit) primarily regulates a smaller group of proteins involved in DSB 
end joining.  Following the recognition of DNA damage by different sensor 
proteins, these kinases trigger the direct or indirect phosphorylation of numerous 
effector proteins involved in a multitude of signaling networks that promote 
different DNA repair processes, cell-cycle arrest and programmed cell death 
(Jackson and Bartek, 2009; Ciccia and Elledge, 2011).  Though the majority of 
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the understanding of these DNA damage-associated PIKKs pertains to their 
specific canonical damage response pathways, these kinases are increasingly 
being implicated in the regulation of additional signaling pathways.  Activation of 
ATM is observed in response to replication stress resultant from hypoxia or 
chloroquine treatment (in the absence of apparent DSBs), as a step in the mitotic 
spindle checkpoint, and is implicated in insulin signaling and regulation of 
oxidative stress (Shiloh and Ziv, 2013).  ATR has a role in coordinating DNA 
replication origin firing and maintaining replication fork stability (Nam and Cortez, 
2011), and DNA-PK is implicated in regulating cell proliferation and regulation of 
oxidative stress (Shiloh and Ziv, 2013). 
Included among the various PIKK substrates is p53.  p53 is 
phosphorylated on a number of residues, primarily clustered in the N- and C-
terminal regions (Figure 1.1), in response to various DNA-damaging agents 
(Meek and Anderson, 2009; Meek, 2015).  Phosphorylation of C-terminal 
residues is primarily thought to influence site-specific DNA binding by p53, 
whereas N-terminal phosphorylation events have been implicated in regulating 
the Mdm2-p53 interaction as well as p300/CBP recruitment (Meek and Anderson, 
2009; Meek, 2015).  Seven serines (Ser6, 9, 15, 20, 33, 37, 46) and two 
threonines (Thr18 and 81) in the N-terminal region of human p53 are 
phosphorylated in response to exposing cells to ionizing radiation or UV light 
(Meek and Anderson, 2009).  These majority of these phosphorylation events 
occur directly by ATM, ATR, or DNA-PK (Lees-Miller et al., 1992; Banin et al., 
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1998; Canman et al., 1998; Tibbetts et al., 1999) or indirectly by the ATR- and 
ATM-activated checkpoint kinases Chk1 or Chk2 (Shieh et al., 2000; Hirao et al., 
2000; Saito et al., 2002).  Additionally, Casein kinase 1 (CK1) has also been 
shown to phosphorylate a number of these residues (Dumaz et al., 1999; 
Higashimoto et al., 2000). 
Of particular interest in the search for the mechanism of p53 stabilization 
following DNA damage were residues Ser15 and Ser20 (Ser18 and Ser23 in 
mice).  In vitro experiments revealed phosphorylation of Ser15, a target of both 
ATM and ATR, inhibits the p53-Mdm2 interaction (Shieh et al., 1997) and 
coincides with p53 activation (Siliciano et al., 1997).  Similar experiments have 
shown phosphorylation of Ser20, a target of Chk2, leads to reduced Mdm2-
medated degradation of p53 and increased p53 activity (Unger et al., 1999; 
Chebab et al., 1999; Hirao et al., 2000).  Furthermore, Thr18 phosphorylation, 
which occurs through CK1 and can disrupt Mdm2-p53 binding, was shown to be 
dependent on prior Ser15 phosphorylation (Dumaz et al., 1999; Sakaguchi et al., 
2000).  
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Figure 1.1:  Diagram of the p53 protein.  Shown are the major functional 
domains along with sites of phosphorylation relevant to the DNA damage 
response (P, yellow circles).  TAD, transcriptional activation domain; PRD, 
proline-rich domain; TET, tetramerization domain; REG, C-terminal regulatory 
region; NLS, nuclear localization sequence; NES, nuclear export sequence. 
 
As these p53 residues are located within, or immediately adjacent to, the 
Mdm2-p53 binding interface (Kussie et al., 1996), it was hypothesized that 
phosphorylation of these residues was sufficient to account for p53 stabilization 
and activation following DNA damage.  However, analysis of various genetically 
engineered mouse models, which allowed for the examination of these 
phosphorylation events under endogenous conditions, revealed that these 
phosphorylation events were insufficient to account for the full effects of DNA 
damage on p53 stabilization and activation or for p53 tumor suppression (Wu et 
al., 2002; Chao et al., 2003; Sluss et al., 2004; MacPherson et al., 2004; Chao et 
al., 2006).   
p53S18A mice in which serine 18 (Ser15 in humans) is replaced with 
alanine show no significant defects in p53 protein stabilization in thymocytes or 
MEFs in response to DNA damage (Chao et al., 2003; Sluss et al., 2004).  MEFs 
from p53S18A mice show no defects in proliferation or growth arrest after DNA 
		 	 	 26	
damage, while thymocytes show an intermediate (compared to p53 / ) defect in 
apoptosis.  However, the ability of p53 to transactivate a number of target genes 
is compromised in p53S18A mice.  A recent report suggests that this may be due 
to a role for p53 Ser15 in transcription and promoter relaxation as opposed to 
p53 stabilization (Loughery et al., 2014).  Additionally, while p53S18A mice do not 
develop spontaneous tumors, they do develop Eµ-myc-driven B cell lymphomas 
at an accelerated rate, possibly due to their apoptotic defects (Sluss et al., 2010). 
p53S23A mice in which serine 23 (Ser20 in humans) is replaced with 
alanine, show a similar absence of defects in p53 stabilization or growth arrest 
MEFs (Wu et al., 2002; MacPherson et al., 2004).  However, p53S23A mice do 
show reduced stabilization of p53 and apoptosis in thymocytes in response to IR, 
though intermediate compared to p53 /   thymocytes (MacPherson et al., 2004).  
Furthermore, p53S23A mice develop spontaneous tumors (predominantly B cell 
lymphomas) with an earliest onset of approximately 12 months and 
approximately 70% of animals having developed tumors by 24 months.  
Interestingly, p53S18A/S23A mice, in which both Ser18 and Ser23 have been 
substituted, display more profound deficiencies in p53 stabilization and function, 
indicating an additive effect of phosphorylation of these two residues in regulating 
p53 function (Chao et al., 2006).  While still intermediate to the phenotypes 
observed in ATM /  and p53 /  cells, thymocytes from p53S18A/S23A mice show more 
significantly impaired p53 stabilization, transactivation of target genes, and 
apoptosis in response to irradiation than either single-mutant alone.  However, 
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p53 stabilization and activities are still unperturbed in MEFs.  These mice are 
similarly tumor prone as reported for Ser23 mutant mice, and again present 
primarily with lymphomas. 
 
DNA damage-induced modifications of Mdm proteins 
As the in vivo results obtained from p53 knock-in mice failed to replicate 
the profound defects in DNA damage-induced p53 stabilization and activity 
predicted by in vitro studies, additional signaling events must contribute to this 
process.  In addition to p53, its primary negative regulators Mdm2 and MdmX are 
also subject to a multitude of phosphorylation events in response to DNA 
damage (Figures 1.2, 1.3). 
 
Phosphorylation of the Mdm2 acidic domain 
Located in the acidic domain of Mdm2 is a cluster of residues that are 
phosphorylated under homoeostatic conditions (Hay and Meek, 2000).  
Phosphorylation of these residues is known to occur through the activities of the 
kinases Glycogen Synthase Kinase 3b (GSK-3b), Casein Kinase 1 (CK1), and 
CK2 (Hjerrild et al., 2001; Winter et al., 2004; Allende-Vega et al., 2005; Kulikov 
et al., 2005).  Phosphorylation of these residues improves Mdm2-mediated 
turnover of p53 in the absence of stress stimuli (Blattner et al., 2002; Hjerrild et 
al., 2001; Kulikov et al., 2005), and hypo-phosphorylation of this region of Mdm2 
is reported to coincide with DNA damage-induced p53 stabilization (Blattner et 
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al., 2002).  Accordingly, inhibition of GSK-3b leads to p53 stabilization in cells 
(Kulikov et al., 2005).  Notably, GSK-3b is inhibited through phosphorylation by 
Akt, which is activated by DNA-PK following DNA damage (Boehme et al., 2008).  
Akt-mediated inhibition of Mdm2 activity in this context contrasts with other 
reports in which the direct phosphorylation of Mdm2 Ser166 and Ser186 by Akt is 
proposed to inhibit p53 activity by facilitating Mdm2 translocation into the nucleus 
(Mayo and Donner, 2001; Zhou et al., 2001) and by inhibiting Mdm2 self-
ubiquitination and degradation (Feng et al., 2004).  
 
Mdm protein phosphorylation by ATM 
In response to DNA damage, human MdmX is phosphorylated at Ser342 
and Ser367 by Chk2 (Chen et al., 2005a; Okamoto et al., 2005; LeBron et al., 
2006; Pereg et al., 2006) and Ser403 by ATM (Pereg et al., 2005).  These 
phosphorylation events lead to MdmX degradation, concurrent with p53 
stabilization and activation (Chen et al., 2005a; Okamoto et al., 2005).  This 
phosphorylation-dependent degradation of MdmX is proposed to be directed by 
Mdm2, and possibly mediated by changes in MdmX binding by 14-3-3 and the 
deubiquitinase HAUSP (Meulmeester et al., 2005; Okamoto et al., 2005; LeBron 
et al., 2006; Pereg et al., 2006).  Wahl and colleagues have generated an 
MdmX3SA mouse model in which all three of these serine residues are replaced 
with alanine (Wang et al., 2009).  MdmX3SA mice display impaired p53 
stabilization and decreased p53 activity in response to IR.  Furthermore, 
		 	 	 29	
MdmX3SA mice are resistant to lethal doses of IR, and though not prone to 
spontaneous tumorigenesis, these mice display increased Eμ-myc-driven 
lymphomagenesis.  Thus, DNA damage-induced phosphorylation of MdmX, a 
negative regulator of p53, can impact p53 stabilization and activity. 
As observed with MdmX, ATM-dependent phosphorylation of Mdm2 
precedes p53 stabilization after DNA damage (Khosravi et al., 1999).  It was 
initially shown that ATM directly phosphorylates Ser395 of human Mdm2 (Ser394 
in mouse) in response to DNA damage (Maya et al., 2001).  Furthermore, in 
transfection-based assays, Mdm2 with an aspartic acid in place of Ser395 
(mimicking phosphorylation) shows a decreased capacity to induce p53 
degradation and nuclear export (Maya et al., 2001).  The phosphatase Wild-type 
p53-induced phosphatase 1 (Wip1) can dephosphorylate Mdm2 Ser395, and 
dephosphorylated Mdm2 has increased stability and affinity for p53, facilitating 
p53 ubiquitination and degradation (Lu et al., 2007).  This result trends with 
another study that showed that DNA damage-induced p53 stabilization is 
preceded by the destabilization of Mdm2, a phenomenon that could be inhibited 
with the PIKK inhibitor wortmannin (Stommel and Wahl, 2004).  However, a 
subsequent study identified five additional residues in the C-terminal region of 
human Mdm2 that are phosphorylated by ATM (Ser386, Ser407, Thr419, Ser425 
and Ser 429) (Cheng et al., 2009) and in vitro work in which all six residues were 
replaced with alanine or aspartic acid suggests that ATM phosphorylation of this 
series of residues inhibits RING domain oligomerization and E3 ligase activity 
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(Cheng et al., 2009; Cheng et al., 2011).  Thus, ATM phosphorylation of Mdm2 is 
proposed to influence both Mdm2 stability and activity towards p53.  
 
 
Figure 1.2:  Diagram of the Mdm2 protein.  Shown are the major functional 
domains along with sites of phosphorylation relevant to the DNA damage 
response (P, yellow circles).  Zn, zinc finger; NLS, nuclear localization sequence; 
NES, nuclear export sequence. 
 
 
Figure 1.3:  Diagram of the MdmX protein.  Shown are the major functional 
domains along with sites of phosphorylation relevant to the DNA damage 
response (P, yellow circles).  Zn, zinc finger. 
 
In order to examine the impact of Mdm2 Ser395 phosphorylation under 
endogenous conditions, our lab has previously reported the generation and initial 
characterization of a mouse model wherein ATM phosphorylation of Mdm2 at 
serine residue 394 (the equivalent of human Mdm2 Ser395) was abolished 
(Mdm2S394A mice) (Gannon et al., 2012).  Cells and tissues in Mdm2S394A mice 
display profound defects in DNA damage-induced p53 protein stabilization and 
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p53 target gene activation.  This failure to induce a robust p53 response 
translates to less p53-dependent apoptosis in hematopoietic tissues, radio-
resistance, and increased spontaneous lymphomagenesis.  Furthermore, 
replacing Mdm2 Ser394 with aspartic acid (Mdm2S394D mice), mimicking 
constitutive phosphorylation at this residue, results in prolonged p53 activity 
following damage and suggests dephosphorylation of this residue is involved in 
resolving the p53 response.  Therefore, ATM phosphorylation of the negative 
regulator of p53, Mdm2, can profoundly impact p53 stabilization and activation in 
response to stress in vivo.  
 
Mdm protein phosphorylation by c-Abl 
Similar to ATM, the c-Abl tyrosine kinase is activated by a variety of DNA 
damaging agents (Kharbanda et al., 1995; Liu et al., 1996; Wang et al., 2011a).   
c-Abl is a member of the Src family of non-receptor tyrosine kinases and was 
discovered as the product of the cellular proto-oncogene from which the Gag-v-
Abl oncogene of the Abelson murine leukemia virus originated (Wang, 2014).  
This finding, coupled with Abl’s role in the Bcr-Abl oncoprotein resultant from the 
Ph+ chromosomal translocation, have led to extensive studies of the oncogenic 
functions of Abl fusion proteins and the current understanding that either Gag or 
Bcr fusion to N-terminally truncated Abl adds to and alters Abl function (Wang, 
2014).  c-Abl is ubiquitously expressed and is ascribed pleiotropic functions 
associated with activity in both the nucleus and cytoplasm (Levav-Cohen et al., 
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2005).  A large number of proteins that are phosphorylated by c-Abl have been 
identified, and include other kinases, adapters, transcription factors, chromatin 
modifiers and cytoskeletal proteins (Wang, 2014).  c-Abl interacts with ATM and 
is phosphorylated on Ser465, leading to its activation (Baskaran et al., 1997; 
Shafman et al., 1997).  This initially led to c-Abl activities in the DNA damage 
response being viewed as downstream of ATM.  However, more recent work has 
shown c-Abl to phosphorylate both ATM and ATR, and that these 
phosphorylation events are required for maximal activity of either PIKK (Wang et 
al., 2011a).  Overexpression studies indicate c-Abl promotes growth arrest in a 
p53-dependent manner, and apoptosis by p53-dependent and independent 
mechanisms (Sawyers et al., 1994; Wen et al., 1996; Yuan et al., 1997).  c-Abl 
mediated p53-independent apoptosis is attributed to the p53 homolog p73, which 
is directly phosphorylated by c-Abl on Tyr99 (Gong et al., 1999; Agami et al., 
1999; Yuan et al., 1999).  However, no c-Abl target residues have been identified 
on p53. 
MdmX is phosphorylated by c-Abl on Tyr55 and Tyr99 in response to DNA 
damage.  These residues are located within the p53 binding domain of MdmX, 
and Tyr99 phosphorylation impairs p53 binding in a transfection-based assay 
(Zuckerman et al., 2009).  Similar co-expression studies have shown that c-Abl 
protects p53 from Mdm2 mediated degradation, and overcomes the inhibitory 
effect of Mdm2 on p53 transcriptional activity and p53-dependent apoptosis 
(Sionov et al., 1999).  Additionally, c-Abl is required for maximal p53 
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accumulation in response to ionizing radiation (IR), doxorubicin, and mitomycin C 
in MEFs, and co-expression of c-Abl overcomes Mdm2 mediated ubiquitination 
and nuclear export of p53 (Sionov et al., 2001).  In vitro studies have shown that 
c-Abl phosphorylates human Mdm2 on Tyr394 (Tyr393 in mouse) as well as 
Tyr276 and Tyr405 (Goldberg et al., 2002; Dias et al., 2006), and that c-Abl 
phosphorylation of Mdm2 Tyr394 impairs Mdm2’s ability to inhibit p53’s 
stabilization and transactivation, and p53-mediated apoptosis (Goldberg et al., 
2002).  It has since been proposed that c-Abl phosphorylation of Mdm2 increases 
Mdm2-MdmX binding and promotes Mdm2-directed MdmX ubiquitination.  This 
increase in MdmX ubiquitination ultimately destabilizes the Mdm2-MdmX 
complex, promoting p53 stabilization (Waning et al., 2011).  However, the 
contribution of these proposed c-Abl-dependent phosphorylation events to p53 
stabilization and activation has not been examined under physiological 
conditions. 
 
Aims of this dissertation 
The principal aim of this dissertation is to further the understanding of the 
mechanisms by which DNA damage response-related kinase signaling affects 
p53 stabilization and activation, and its impact on p53 responses and tumor 
suppression.  Specifically, this dissertation describes the use of several knock-in 
mouse models to examine the effects of Mdm2 phosphorylation by the ATM and 
c-Abl kinases on Ser394 and Tyr393, respectively, under endogenous conditions.  
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Our lab’s previous findings of reduced p53 stabilization and activity, 
radioresistance, and spontaneous tumor susceptibility in Mdm2S394A mice 
highlight a significant role for Mdm2 phosphorylation in regulating p53 activation.  
In Chapter II of this dissertation, we use Mdm2S394A mice to explore in vivo 
the mechanism by which Mdm2 Ser394 phosphorylation alters p53 functions in a 
radiosensitive tissue.  Furthermore, we address whether ATM-Mdm2-p53 
signaling in mice impacts tumorigenesis induced by activated oncogenes or 
ionizing radiation (IR), and explore the role of ATM-Mdm2-p53 signaling in 
promoting IR-mediated bone marrow failure.  Our results indicate that Mdm2 
Ser394 phosphorylation has dramatically different and stress-dependent effects 
in tumorigenesis. 
In Chapter III of this dissertation we present a novel knock-in mouse that 
cannot be phosphorylated at Tyr393 (Mdm2Y393F mice).  Experiments with 
Mdm2Y393F mice allow us to examine the influence of c-Abl phosphorylation of 
Mdm2 on the regulation of p53-mediated DNA damage responses and p53 tumor 
suppression in vivo.  Furthermore, we describe the generation of mice in which 
both Tyr393 and Ser394 cannot be phosphorylated (Mdm2Y393F/S394A mice), 
allowing for the determination of whether phosphorylation of these residues has 
additive effects. 
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CHAPTER II 
Mdm2 Ser394 Phosphorylation Regulates Mdm2 Stability and has 
Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis 
 
ATM phosphorylation of Mdm2 Ser394 is required for robust p53 
stabilization and activation in DNA damaged cells.  We have now utilized 
Mdm2S394A knock-in mice to determine that phosphorylation of Mdm2 Ser394 
regulates p53 activity and the DNA damage response in lymphatic tissues in vivo 
by modulating Mdm2 stability.  Mdm2 Ser394 phosphorylation delays 
lymphomagenesis in Eμ-myc transgenic mice, and preventing Mdm2 Ser394 
phosphorylation obviates the need for p53 mutation in Myc-driven tumorigenesis. 
However, irradiated Mdm2S394A mice also have increased hematopoietic stem 
and progenitor cell functions, and decreased lymphomagenesis in sub-lethally 
irradiated Mdm2S394A mice.  These findings document contrasting effects of ATM-
Mdm2 signaling on p53 tumor suppression, and reveal that destabilizing Mdm2 
by promoting its phosphorylation by ATM would be effective in treating 
oncogene-induced malignancies, while inhibiting Mdm2 Ser394 phosphorylation 
during radiation exposure or chemotherapy would ameliorate bone marrow 
failure and prevent the development of secondary hematological malignancies. 
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Results 
ATM-Mdm2 signaling regulates the p53-response in lymphatic tissues 
To further explore the effects of Mdm2 Ser394 phosphorylation on p53 
protein levels and activity in vivo, we analyzed thymi of mice treated with a low 
dose (1.75 Gy) of IR.  Although p53 protein levels were elevated in the thymus of 
Mdm2S394A mice at 3 hours and 6 hours following IR, there was considerably less 
total p53 protein and phosphorylated p53 phosphorylation (S18) in treated 
Mdm2S394A mice than in irradiated wild-type (WT) mice (Figure 2.1).  This is 
similar to what we observed previously in these mice using higher dosages of IR 
(Gannon et al., 2012).  However, we also noted that basal levels of p53 appeared 
slightly lower in Mdm2S394A thymi than in WT thymi, and more Mdm2 protein 
appeared to be present in Mdm2S394A thymi in the absence of acute DNA-
damage and following IR treatment (Figure 2.1). 
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Figure 2.1: Western blot of thymus extracts.  WT and Mdm2S394A mice were 
left untreated or exposed to 1.75 Gy ionizing radiation (IR) and thymi were 
harvested at 3 and 6 hours.  Protein levels were analyzed by western blotting.  
TKO indicates Mdm2 / , MdmX / , p53 /  control; Tg indicates Mdm2Tg/+ Mdm2 
overexpressing control. 
 
 
 
 
There was a significant decrease in WT Mdm2 protein levels in whole thymus 
following DNA damage, an observation that has been made in cell culture 
settings by several groups (Stommel and Wahl, 2004; Itahana et al., 2007; 
Inuzuka et al., 2010; Malonia et al., 2015).  However, Mdm2 protein levels 
appeared to diminish after IR at a lesser rate in Mdm2S394A thymus than in WT 
thymus.  To more definitively quantify the observed differences in thymic Mdm2 
and p53 levels, we analyzed biological triplicates of untreated and irradiated WT 
and Mdm2S394A thymi.  This confirmed that Mdm2 protein levels were higher in 
Mdm2S394A thymi both before and after treatment, and that the IR-induced relative 
decrease in Mdm2 protein levels was far less in Mdm2S394A thymi (Figure 2.2).  In 
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contrast, the reduction of MdmX levels induced by DNA damage (Wang et al., 
2009) appears to be similar in WT and Mdm2S394A thymi.  Though not statistically 
significant, p53 levels are slightly lower in untreated Mdm2S394A thymi (Figure 2.2, 
lower panel), and are significantly lower in irradiated Mdm2S394A thymi.   
 
 
Figure 2.2: Quantification of thymus Mdm2 and p53 protein levels.  
Biological triplicates of WT and Mdm2S394A mice left untreated or 3 hours after 
exposure to 1.75 Gy were analyzed by western blotting.  Band intensities were 
determined by densitometry.  Mdm2 and p53 levels were normalized for Vinculin 
levels and average values plotted (±SEM).  *P < 0.05, **P < 0.01 (Student’s t-
tests). 
 
 
Although p53 target gene expression was similar in non-damaged WT and 
Mdm2S394A thymi (Figure 2.3), a reduction in IR-activation of p53 target genes 
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was seen in Mdm2S394A thymi.  Reduced expression levels of Mdm2, the cell 
cycle regulator Cdkn1a (p21), and the pro-apoptotic genes Puma, Noxa, and Bax 
are in agreement with reduced levels of p21, Puma, and cleaved Caspase-3 
protein (Figure 2.1), and with a clear reduction in DNA damage-induced 
apoptosis in Mdm2S394A thymi following exposure of mice to low-level IR (Figure 
2.4).   
To explore whether these effects were unique to the thymus, we also 
examined protein levels in spleens of WT and Mdm2S394A mice.  As observed in 
the thymus, there appeared to be less total p53 in Mdm2S394A spleens before and 
after irradiation (Figure 2.5), and Mdm2 levels were higher in both untreated and 
irradiated Mdm2S394A spleens.  Intriguingly, while no induction of Mdm2 protein 
was observed in thymi of WT and Mdm2S394A mice in response to IR, spleens of 
both genotype displayed a more ‘classic’ induction of Mdm2 often seen in 
cultured cells after genotoxic stress.  Similar to what was observed in the thymus, 
decreased levels of p53 and increased levels of Mdm2 in irradiated Mdm2S394A 
spleens correlate with reduced p53 activation (phospho-S18 p53), reduced levels 
of Puma and p21, and reduced levels of cleaved Caspase-3 (Figure 2.5). 
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Figure 2.3: Relative expression 
levels of p53 target genes in 
thymi.  WT and Mdm2S394A mice 
were treated as in Figure 2.1 and 
fold expression of p53-target genes 
was determined by real-time 
quantitative PCR, relative to 
untreated WT samples and using 
Rplp0 as internal reference (n = 3, 
±SEM).  *P < 0.05, **P < 0.01 
(Student’s t-tests). 
Figure 2.4: Apoptosis in thymi.  
TUNEL staining of thymi from WT 
and Mdm2S394A mice treated as in 
Figure 2.1.  Scale bars represent 
100 μm. 
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Figure 2.5: Western blot of spleen extracts.  WT and Mdm2S394A mice were 
left untreated or exposed to 1.75Gy ionizing radiation (IR) and spleens were 
harvested at 3 and 6 hours.  Protein levels were analyzed by western blotting.  
TKO indicates Mdm2 / , MdmX / , p53 /  control; Tg indicates Mdm2Tg/+ Mdm2 
overexpressing control. 
 
ATM phosphorylation of Mdm2 Ser394 governs Mdm2 levels and stability 
In order to directly analyze the effects of Mdm2 Ser394 phosphorylation 
on the stability of Mdm2 in the presence and absence of exogenous DNA 
damage, we measured the half-life of Mdm2 proteins using the protein synthesis 
inhibitor cycloheximide.  Although basal levels of Mdm2 transcription are similar 
in WT and Mdm2S394A thymi, Mdm2 protein levels are elevated in non-damaged 
Mdm2S394A mice (Figures 2.1 and 2.2), suggesting that the mutant Mdm2 protein 
is more stable in the absence of exogenous DNA damage.  However, we 
observed no significant difference in the half-lives of WT Mdm2 and Mdm2S394A in 
untreated thymocytes (80 and 65 minutes respectively, overlapping 95% 
confidence intervals) (Figure 2.6).  But following treatment of the thymocytes with 
2.5 Gy IR, the half-life of WT Mdm2 decreased by more than 50 percent (29 
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minutes) whereas the half-life of Mdm2S394A remained unchanged (69 minutes) 
(Figure 2.7).  These data show that phosphorylation of Mdm2 Ser394 by ATM is 
a crucial event in DNA damage-induced destabilization of Mdm2 under 
physiological conditions. 
  
 
Figure 2.6: Mdm2 protein stability in untreated thymocytes.  Thymocytes 
harvested from WT and Mdm2S394A mice (n = 6) were treated with 100 mg/mL 
cycloheximide and harvested at the indicated time points.  The levels of Mdm2 
and α-tubulin were analyzed by western blotting.  Band intensities were 
determined by densitometry and Mdm2 levels normalized to α-tubulin were 
plotted.  One-phase decay curves were fitted using GraphPad Prism software. 
 
 
 
 
Figure 2.7: Mdm2 protein stability in irradiated thymocytes.  Thymocytes 
harvested from WT and Mdm2S394A mice (n = 6-8) were exposed to 2.5Gy IR and 
treated with 100 mg/mL cycloheximide and harvested at the indicated time 
points.  Normalized Mdm2 levels were plotted as in Figure 2.6. 
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As previous studies have shown ATM phosphorylation of Mdm2 to impact the 
ability of Mdm2 to promote p53 degradation (Maya et al., 2001; Cheng et al., 
2009; Cheng et al., 2011), we also examined whether p53 stability was affected 
in the presence and absence of DNA damage.  We observed no difference in the 
half-life of p53 in non-treated WT versus Mdm2S394A thymocytes (Figure 2.8).  As 
expected, DNA damage stabilized p53 levels in WT cells (Figure 2.9).  Likewise, 
DNA damage stabilized p53 levels in Mdm2S394A thymocytes, albeit to a lower 
level than seen in WT thymocytes. 
 
 
Figure 2.8: p53 protein stability in untreated thymocytes.  Thymocytes 
harvested from WT and Mdm2S394A mice (n = 6) were treated with 100 mg/mL 
cycloheximide and harvested at the indicated time points.  The levels of p53 and 
α-tubulin were analyzed by western blotting.  Band intensities were determined 
by densitometry and p53 levels normalized to α-tubulin were plotted.  One-phase 
decay curves were fitted using GraphPad Prism software. 
 
 
		 	 	 44	
 
Figure 2.9: p53 protein stability in irradiated thymocytes.  Thymocytes 
harvested from WT and Mdm2S394A mice (n = 6-8) were exposed to 2.5Gy IR and 
treated with 100 mg/mL cycloheximide and harvested at the indicated time 
points.  Normalized p53 levels were plotted as in Figure 2.8. 
 
Since we observed no difference in the rate of p53 decay in Mdm2S394A 
and WT thymocytes, it is possible that phosphorylation of Mdm2 Ser394 
upregulates p53 activity not only by altering p53 protein stability but by also 
inhibiting Mdm2-p53 complex formation and Mdm2-mediated steric inhibition of 
p53 transcriptional activation.  Therefore, we examined the effects of Mdm2 
Ser394 phosphorylation on Mdm2-p53 binding in the presence and absence of 
DNA damage in whole tissue extracts.  In an effort to control for potential 
differences in antibody affinity following IR-induced modification of Mdm2, Mdm2 
was immunoprecipitated from untreated and irradiated thymus lysates in 
separate experiments with two distinct antibodies whose epitopes reside in 
opposing termini of Mdm2 (Figure 2.10, left).  In both cases, more p53 co-
immunoprecipitated with Mdm2S394A than WT Mdm2 in untreated thymi, whereas 
similar amounts of p53 co-immunoprecipitated with Mdm2 in irradiated 
Mdm2S394A and WT thymi.  As there was less p53 observed in the total lysates of 
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untreated and irradiated Mdm2S394A thymi relative to WT thymi (Figure 2.10, 
right), this result reveals increased levels of Mdm2-bound p53 (relative to total 
p53) in undamaged and IR-treated Mdm2S394A thymi.  We confirmed this finding 
by performing the reciprocal experiment using p53 immunoprecipitation, and 
observed that equivalent amounts of Mdm2 co-immunoprecipitated with lesser 
amounts of p53 in untreated and irradiated Mdm2S394A thymi.  Additional 
immunoprecipitation experiments against MdmX detected no effect on the 
relative amounts of Mdm2-bound MdmX or p53-bound MdmX before or after 
DNA damage (Figure 2.11). 
 
 
Figure 2.10: Reciprocal co-immunoprecipitation of Mdm2 and p53 from 
thymus extracts.  Thymus protein extracts from WT and Mdm2S394A mice 
untreated or exposed to 5 Gy IR were immunoprecipitated with antibodies for 
Mdm2 (NBP1-02158 (Ab-I) and Ab-5 (Ab-II)) and p53 (left).  Immunoprecipitates 
were analyzed by western blotting for Mdm2 and p53.  Total lysate (10% input) 
was analyzed by western blotting (right). 
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Figure 2.11: Co-immunoprecipitation of Mdm2 and p53 with MdmX from 
thymus extracts.  Thymus protein extracts from WT and Mdm2S394A mice 
untreated and exposed to 5Gy IR were immunoprecipitated with an antibody for 
MdmX (MDMX-82; Sigma) (top).  Immunoprecipitates were analyzed by western 
blotting for Mdm2 and p53.  Total lysate (10% input) was analyzed by western 
blotting (bottom). 
 
Collectively, these data reveal that phosphorylation of Mdm2 Ser394 
under basal conditions and following acute IR exposure reduces Mdm2 stability, 
thereby reducing the relative amount of Mdm2-bound p53.  This reduction in 
Mdm2-p53 complex negatively impacts Mdm2 inhibition of p53 target gene 
transactivation as well as Mdm2 destabilization of p53.   
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Accelerated Eμ-myc driven lymphomagenesis in Mdm2S394A mice 
We have previously described an increased susceptibility to spontaneous 
tumorigenesis in Mdm2S394A mice (Gannon et al., 2012).  We next sought to 
examine the effects of Mdm2 Ser394 phosphorylation on oncogene-induced 
tumorigenesis.  Mdm2S394A mice were bred to Eμ-myc transgenic mice to 
generate Eμ-myc and Eμ-myc;Mdm2S394A mice.  Eμ-myc mice succumb to pre-
B/B-cell lymphomas within 3-6 months of age.  We observed a median time to 
tumor presentation of 126 days in Eμ-myc mice, consistent with previous studies 
(Adams et al., 1985; Eischen et al., 1999; Sluss et al., 2010) (Figure 2.12).  In 
contrast, the median time to tumor presentation in Eμ-myc;Mdm2S394A mice was 
only 71 days.  This represents a nearly 50% reduction in the time to Myc-induced 
tumorigenesis when ATM phosphorylation of Mdm2 Ser394 is inhibited.  All 
tumor-bearing Eμ-myc mice and Eμ-myc;Mdm2S394A mice presented with 
enlarged lymph nodes and spleens, and representative tumors were examined 
histologically by haematoxylin and eosin (H&E) staining.  Both genotypes 
developed similar, high-grade lymphomas, composed of monotonous populations 
of pre-B/B cells.  Tumors displayed high levels of mitosis and apoptosis, and the 
characteristic “starry-sky” pattern resultant from abundant tingible body-laden 
macrophages.  The cell type was further confirmed by immunohistochemistry 
(IHC) through positive staining for B220/CD45R (Figure 2.13). 
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Figure 2.12: Lymphomagenesis in 
Eμ-myc and Eμ-myc;Mdm2S394A 
mice.  Kaplan-Meier survival curves 
of Eμ-myc (n = 16) and Eμ-
myc;Mdm2S394A (n = 11) mice.  
Median survival times were as 
follows: Eμ-myc (125.5 days) and 
Eμ-myc;Mdm2S394A (71 days).  
Curves were compared by Log-rank 
test: P < 0.0001. 
Figure 2.13: Representative 
staining of Eμ-myc and Eμ-
myc;Mdm2S394A lymphomas.  B cell 
lymphomas from lymph nodes of Eμ-
myc (98 days) and Eμ-
myc;Mdm2S394A (80 days) mice were 
stained by haematoxylin and eosin 
(top) and with an antibody specific 
for B220 (bottom).  Scale bars 
represent 100 μm.
 
 
Myc-driven B cell tumors face selective pressure to inactivate the p53 
pathway through p53 mutation, Mdm2 overexpression, or by loss of Arf (Eischen 
et al., 1999).  We examined the status of p53, Mdm2 and Arf in a panel of ten 
tumors that developed in Eμ-myc;Mdm2S394A mice (Figure 2.14).  No marked 
differences in p53 protein levels were observed in any of the ten tumors 
examined.  However, Arf levels appeared more variable, with loss of detectable 
Arf protein seen in four of the ten tumors.  RT-PCR confirmed that three of those 
four tumors did not express full length Arf mRNA.  Arf levels have been shown 
previously to be elevated in cases where p53 is mutant and the negative 
feedback loop between p53 and Arf is disrupted, and we identified several 
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tumors wherein Arf appeared to be increased.  However, sequencing of the 
entire p53 coding sequence of all ten tumors revealed no mutations in p53 gene 
transcripts.  Thus, the observed variability in Arf levels within the Myc tumors was 
not a result of p53 status.  Furthermore, Mdm2 protein levels did not vary 
significantly between tumors, and qPCR analysis also failed to detect alterations 
in Mdm2 transcript levels in any tumor (data not shown).  Thus, ATM 
phosphorylation of Mdm2 Ser394 strongly suppresses Myc oncogene-induced 
tumorigenesis in mice, and inhibition of this signaling event obviates the need for
mutation of the Mdm2-p53 tumor suppressor axis in Myc-driven B cell 
lymphomagenesis (Figure 2.15). 
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Figure 2.14: Eμ-myc;Mdm2S394A 
tumor analysis.  The levels of 
Mdm2, p53 and Arf were analyzed 
by western blotting in a panel of Eμ-
myc;Mdm2S394A tumors.  RT-PCR 
confirmed that full-length Arf 
message was absent in 3 of 10 
tumors (2nd from bottom).  p53 cDNA 
was sequenced for each tumor, 
revealing no mutations (bottom).  LN, 
lymph node; Spl, spleen. 
Figure 2.15: Schematic outlining 
the proposed methods of p53 
activation by Myc.  Tumors in mice 
in which Mdm2 is WT select for loss 
of Arf or p53, or Mdm2 
overexpression (Eischen et al., 
1999).  We propose that Mdm2S394A 
mice obviate the need for p53 loss or 
Mdm2 overexpression by mitigating 
the effects of the DDR arm of Myc 
signaling to p53.
Mdm2S394A mice are resistant to IR-induced lymphomagenesis 
We next sought to examine the effects of ATM phosphorylation of Mdm2 
Ser394 on IR-induced tumorigenesis.  Exposure of mice to repeated low-dose IR 
promotes the development of thymic lymphomas (Kaplan and Brown, 1952).  
This lymphomagenesis is significantly enhanced in the absence of p53 (Kemp et 
al., 1994; Labi et al., 2010; Michalak et al., 2010).  As we have shown that IR-
induced p53 activity is diminished in both the thymus and spleen of Mdm2S394A 
mice, we anticipated a heightened sensitivity to IR-induced lymphomagenesis in 
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this model.  Cohorts of WT, Mdm2S394A, p53+/  and p53 /  mice were subjected to 
four weekly doses of 1.75 Gy IR and monitored over time for tumor presentation.  
89% of WT mice developed lymphomas by 400 days, with a median survival of 
197 days (Figure 2.16), consistent with a previous study employing this dosing 
strategy (Labi et al., 2010).  Also consistent with previous studies was the 
significant acceleration of lymphomagenesis observed in the absence of p53 
(Kemp et al., 1994; Labi et al., 2010; Michalak et al., 2010).  All p53 /  mice 
developed lymphomas within 151 days, with a median survival of 131 days, 
whereas all p53+/  mice developed lymphomas within 167 days, with a median 
survival of 154 days.  Surprisingly, Mdm2S394A mice proved to be highly resistant 
to IR-induced thymic lymphomagenesis.  Although tumor presentation in 
Mdm2S394A mice followed similar initial kinetics as observed in WT mice, only 
42% of Mdm2S394A mice developed lymphoma, with a median survival among 
tumor-bearing mice of 184 days.  Tumor-bearing animals presented with 
profoundly enlarged thymi, as well as frequent splenomegaly and hepatomegaly.  
Histological analyses of H&E stained tissues showed disorganized, hyperplastic 
lymphatic tissues as well as significant lymphocyte infiltration in portal regions of 
the liver (Figure 2.17).  Immunohistochemistry confirmed that the lymphomas 
arising in IR-treated mice were T cell-derived, with positive staining for CD3 and 
negative staining for B220 (Figure 2.18).  Thus, in contrast to their increased rate 
of spontaneous and oncogene-induced tumorigenesis, Mdm2S394A mice are 
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actually more resistant to radiation-induced T cell lymphomagenesis than WT 
mice, despite having clear defects in p53-mediated thymic apoptosis.  
  
 
 
Figure 2.16: IR-induced tumorigenesis.  Kaplan-Meier survival curves of WT (n 
= 20), Mdm2S394A (n = 19), p53+/  (n = 9) and p53 /  (n = 7) mice exposed to 7 Gy 
cumulative IR.  Median survival times were as follows: WT (185 days), 
Mdm2S394A (n.d.), p53+/  (154 days) and p53 /  (131 days).  Curves were 
compared by log-rank test: WT to p53 /  (P < 0.0001), WT to p53+/  (P < 0.0001), 
WT to Mdm2S394A (P = 0.0007), Mdm2S394A to p53+/  (P < 0.0001), Mdm2S394A to 
p53 /  (P < 0.0001). 
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Figure 2.17: H&E staining of IR-induced lymphomas.  Tissue sections of 
lymphomas that developed in the thymus, spleen and liver of WT and Mdm2S394A 
mice stained with haematoxylin and eosin at 10X (left) and 40X (right) 
magnification.  Scale bars represent 100μm. 
 
 
 
 
Figure 2.18: Immunohistochemical staining of IR-induced lymphomas.  
Tissue sections of lymphomas that developed in the thymus, spleen and liver of 
WT and Mdm2S394A mice stained with antibodies specific for CD3 (left) and B220 
(right).  Scale bars represent 100μm. 
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Radiation resistance in Mdm2S394A mice is dictated by improved bone 
marrow recovery following IR 
We have previously reported that Mdm2S394A mice are resistant to 
threshold-lethal doses (8 Gy) of radiation.  To better understand why ATM 
phosphorylation of Mdm2 Ser394 would promote radiation-induced 
lymphomagenesis yet provide resistance to acute radiation, we decided to 
examine further the response of these mice to whole-body IR.  The primary 
cause of lethality in mice subjected to IR doses as high as 10 Gy is a p53-
dependent ablation of the bone marrow compartment, known as “hematopoietic 
syndrome” (Komarova et al., 2004).  Previous reports have revealed that even 
small changes in p53 activity can profoundly impact the hematopoietic system 
(Mendrysa et al., 2003; Terzian et al., 2007; Wang et al., 2011c; Pant et al., 
2013), and hematopoietic failure phenotypes have previously been described in 
mice bearing hypomorphic or reduced copies of functional Mdm2 alleles 
(Mendrysa et al., 2003; Terzian et al., 2007).  Furthermore, several p53 target 
genes, including those encoding p21 or Puma have been implicated in governing 
the radiosensitivity of murine bone marrow (Cheng et al., 2000; van Os et al., 
2007; Shao et al., 2010; Yu et al., 2010; Wang et al., 2011c; Pant et al., 2013). 
To elucidate the basis for the acute radioresistance of Mdm2S394A mice, we 
examined the expression of the p53-target genes Mdm2, p21, Puma and Noxa by 
qPCR in the bone marrow of WT, Mdm2S394A and p53 /  mice before and after 
irradiation (Figure 2.19).  As we observed in the thymus, no differences were 
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present in the expression levels of any of the examined p53 target genes in 
untreated Mdm2S394A bone marrow.  Similar expression levels of the target genes 
were observed in untreated p53 /  mice.  Following whole body treatment of mice 
with 5 Gy IR, the expression levels of all four genes increased dramatically in WT 
bone marrow, indicative of a strong p53 response.  However, lower levels of p21, 
Puma and Noxa transcripts were detected in Mdm2S394A bone marrow, indicating 
reduced p53 activity in this tissue.  Although Mdm2 transcript levels did not 
appear to be overtly reduced in irradiated Mdm2S394A bone marrow, no induction 
of Mdm2, p21 or Puma transcription was observed in the bone marrow of p53-
deficient mice, pointing to the p53-dependence of their induction following 
irradiation. 
 
 
 
Figure 2.19: Relative expression levels of p53-target genes in bone marrow.  
Bone marrow was harvested from WT, Mdm2S394A and p53 /  mice left untreated 
(N.T.) or 6 hours after 5Gy IR (IR).  Fold expression was determined by real-time 
quantitative PCR, relative to untreated WT samples, using Rplp0 as internal 
reference (n = 3-4 mice, ±SEM).  *P < 0.05, **P < 0.01 (Student’s t-tests of ΔΔCt 
values). 
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We next examined the bone marrow of WT, Mdm2S394A and p53 /  mice by 
H&E staining at intervals up to 9 days following exposure to 8 Gy IR (Figure 
2.20).  To our surprise, all mice examined showed a dramatic decrease in 
cellularity at 1 and 3 days following irradiation, to the point where the three 
genotypes were phenotypically indistinguishable.  Although WT bone marrow 
continued to display a progressive loss of cellularity at day 6 after IR, large 
colonies of cells had appeared in the bone marrow of Mdm2S394A and p53 /  mice 
at this time (Figure 2.20 - see arrows).  By 9 days post-IR, the colonies present in 
Mdm2S394A and p53 /  mice had expanded significantly and often bridged the 
medullary cavity, whereas only a few smaller colonies were observed in WT bone 
marrow.  Immunohistochemical staining for CD45 confirmed that the colonies 
were of hematopoietic origin (data not shown).  The timing of the increased bone 
marrow cellularity in Mdm2S394A and p53 /  mice (but not in WT mice) is likely 
significant, as it precedes by one day the onset of mortality observed in WT mice 
treated with 8 Gy IR (Gannon et al., 2012). 
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Figure 2.20: Haematoxylin and eosin stained bone marrow following 
exposure to 8 Gy IR.  Femurs from WT, Mdm2S394A and p53 /  mice were 
harvested at daily intervals following exposure to 8 Gy IR. Blue arrows indicate 
nascent hematopoietic cell colonies.  Scale bars represent 100 μm. 
 
 
It has been shown that mice undergoing hematopoietic recovery produce 
primarily myeloerythroid cells, and myeloerythroid-restricted progenitors are 
sufficient to confer radioprotection (Uchida et al., 1994; Na Nakorn et al., 2002).  
We further characterized the bone marrow colonies by IHC staining for the 
erythroid marker TER-119 (Figure 2.21).  Consistent with previous findings, we 
found that approximately 25% of nucleated bone marrow cells and all mature 
erythrocytes stained positive for TER-119 in the untreated bone marrow of mice 
irrespective of their genotype (Kina et al., 2000).  However, at 9 days post-8 Gy 
IR treatment, only the few remaining mature erythrocytes in the WT bone marrow 
stained positive for TER-119, whereas all of the large colonies present in 
Mdm2S394A and p53 /  bone marrow were predominantly TER-119 positive.  Thus, 
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the p53-dependant resistance to hematopoietic syndrome observed in 
Mdm2S394A and p53 /  mice following whole body IR is linked to the increased 
capability of these models to repopulate their erythroid cell compartment. 
 
 
Figure 2.21: Immunohistochemical staining for TER-119 in bone marrow.  
Bone marrow sections from WT and Mdm2S394A mice left untreated, or 9 days 
after 8 Gy IR.  Scale bars represent 100 μm. 
 
Radiation resistance in Mdm2S394A mice is governed by hematopoietic stem 
and progenitor cells  
In order to characterize the cell type responsible for the increase in bone 
marrow repopulation and subsequent radioresistance observed in Mdm2S394A 
mice, we utilized flow cytometry to examine total bone marrow harvested 24 
hours after treatment with IR.  No differences were observed in the numbers of 
lineage-defined, mature hematopoietic cells in untreated WT or Mdm2S394A mice 
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(Figure 2.22).  Furthermore, no differences were observed in the numbers of 
mature hematopoietic cells in irradiated WT or Mdm2S394A bone marrow, save for 
slightly higher numbers of surviving B cells (p=0.046) in Mdm2 mutant mice.  
These results are in keeping with the lack of a histopathological difference in the 
initial loss of cellularity in irradiated WT and Mdm2S394A bone marrow.   
 
 
Figure 2.22: Quantification of lineage-defined hematopoietic cells in bone 
marrow.  Bone marrow from WT and Mdm2S394A mice was analyzed by flow 
cytometry in the absence of treatment (left) and 24 hours after exposure to 5 Gy 
IR (right) (n = 3-4, ±SEM).  *P < 0.05, **P < 0.01 (Student’s t-tests). 
 
In addition, no difference was observed in the numbers of Lin−Sca1−cKit+ (L−S−K) 
common myeloid progenitors (CMPs) in untreated WT and Mdm2S394A bone 
marrow, or in WT and Mdm2S394A bone marrow following irradiation (Figure 2.23, 
left).  This was confirmed by in vitro colony forming assays performed using the 
bone marrow of untreated and irradiated WT and Mdm2S394A mice (Figure 2.24).  
While there was no difference in the numbers of Lin−Sca1+cKit+ (L−SK) 
hematopoietic stem and progenitor cells (HSPCs) in untreated WT and 
Mdm2S394A bone marrow, there were significantly more HSPCs present in 
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Mdm2S394A bone marrow than in WT bone marrow following irradiation (Figure 
2.23, right).  This finding indicates that the radioresistance observed in 
Mdm2S394A mice is due to reduced loss and/or increased function of HSPCs in 
this model following IR exposure. 
 
 
Figure 2.23: Quantification of L−S−K (CMP) and L−SK (HSPC) cells in bone 
marrow.  Bone marrow from WT and Mdm2S394A mice was analyzed by flow 
cytometry in the absence of treatment (N.T.) and 24 hours after exposure to 5Gy 
IR (IR) (n = 3-4, ±SEM).  *P < 0.05, **P < 0.01 (Student’s t-tests). 
 
 
 
 
Figure 2.24: Colony-forming cell (CFC) assays.  Total bone marrow was 
harvested from WT and Mdm2S394A mice left untreated, or 1 or 96 hours after 
exposure to 5 Gy IR.  Colony-forming cell (CFC) assays (MethoCult 3434 and 
MethoCult 3630; StemCell Technologies) were carried out in accordance with 
manufacturer’s instructions (n = 3-6, ±SEM). 
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We further examined the HSPCs of Mdm2S394A mice by performing in vivo 
competitive repopulation assays.  Mdm2S394A bone marrow expressing the 
CD45.2 leukocyte marker and WT bone marrow expressing the CD45.1 
leukocyte marker were transplanted in a 1:1 ratio into lethally irradiated WT 
(CD45.1) recipient mice (Figure 2.25).  Peripheral blood analysis at 4, 8 and 10 
weeks following transplantation showed gradually increasing relative 
contributions to the hematopoietic lineage of Mdm2S394A bone marrow (62%, 69% 
and 72%, respectively) (Figure 2.26).  This indicated that Mdm2S394A HSPCs 
have an inherent advantage relative to WT HSPCs in their ability to repopulate 
the hematopoietic compartment of lethally irradiated mice.  In addition, we 
irradiated a cohort of the same bone marrow-chimeric mice at 8 weeks post-
transplantation and assayed the relative contributions of WT and Mdm2S394A 
bone marrow, 1 and 12 days later (Figure 2.27).  Relative contributions of 21% 
WT and 78% Mdm2S394A were observed in the untreated bone marrow of 
reconstituted mice.  No significant changes were observed in the percentages of 
WT and Mdm2S394A bone marrow at 1 day after IR (18% and 81%, respectively).  
However, a significant shift towards a greater proportion of Mdm2S394A bone 
marrow was observed (8% WT, 91% Mdm2S394A) in the reconstituted mice 12 
days after IR.   
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Figure 2.25: Experimental design of bone marrow repopulation assays. 
 
 
Figure 2.26: WT and Mdm2S394A competitive bone marrow reconstitution.  
Leukocyte marker analysis of peripheral blood of recipient mice diagramed in 
Figure 2.25 at 4 (n = 15), 8 (n = 15) and 10 (n = 5) weeks after bone marrow 
transplantation (±SEM).  **P < 0.01 (Student’s t-tests). 
 
 
 
Figure 2.27: Post-IR relative contribution of WT and Mdm2S394A chimeric 
bone marrow.  Leukocyte marker analysis of total bone marrow of recipient mice 
diagrammed in Figure 2.25, untreated, 1 and 12 days after exposure to 5Gy IR (n 
= 5, ±SEM).  *P < 0.05, **P < 0.01 (Student’s t-tests). 
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These results confirm that Mdm2S394A HSPCs have a greater capacity to 
repopulate irradiated bone marrow and determine that Mdm2S394A HSPCs display 
greater stem cell function after genotoxic insult.  Furthermore, increased 
Mdm2S394A HSPC cell function is cell-autonomous, as Mdm2S394A HSPCs 
outperform WT HSPCs in a WT microenvironment. 
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Materials and Methods 
Mice and Animal Studies 
All animals described in this study were on a C57Bl/6 background.  Mice and 
cells were irradiated with a cesium-137 source (Gammacell 40).  The generation 
of Mdm2S394A mice has been previously described (Gannon et al, 2012).  Eμ-myc 
mice were a gift from Christine Eischen (Vanderbilt University).  Mice in Eμ-myc 
tumor assays were virgin and inherited the Eμ-myc allele paternally.  For IR-
induced tumor assays, mice 31±3 days of age were irradiated weekly with 1.75 
Gy for 4 weeks (7 Gy cumulative dose).  For bone marrow transplantation 
experiments, recipient CD45.1 mice received 11 Gy of whole body irradiation in a 
split dose (2 ´ 5.5 Gy, 4 hours apart).  Irradiated recipients were reconstituted by 
i.v. injection of 2 × 106 bone marrow cells (1:1 mixture of WT and Mdm2S394A).  All 
animals used in this study were maintained and assayed in accordance with 
federal guidelines and those established by the Institutional Animal Care and Use 
Committee at the University of Massachusetts Medical School. 
 
Protein Analysis 
Tissues and cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 
mM NaCl, 0.5% NP-40) or in CelLytic MT Cell Lysis Reagent (Sigma), 
supplemented in both cases with protease and phosphatase inhibitor cocktail 
tablets (Roche).  Protein extracts were analyzed by direct western blotting or 
immunoprecipitation/western blotting.  Immunoprecipitations were performed on 
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500 µg whole thymus lysate with antibodies specific for Mdm2 (NBP1-02158; 
Novus (Ab-I) and Ab-5; Calbiochem (Ab-II)), p53 (CM5; Novocastra) and MdmX 
(MDMX-82; Sigma), using PureProteome Protein A/G Mix Magnetic Beads 
(Millipore).  Mdm2 Ab-I immunoprecipitates were counterblotted with Mdm2 (Ab-
5; Calbiochem (Ab-II)) and p53 (IMX25; Novocastra) antibodies.  Mdm2 Ab-II 
immunoprecipitates were counterblotted with Mdm2 (NBP1-02158; Novus (Ab-I)) 
and p53 (CM5; Novocastra) antibodies.  Western blotting was performed with 
antibodies specific for Mdm2 (NBP1-02158; Novus and Ab-5; Calbiochem), p53 
(CM5; Novocastra), MdmX (MDMX-82; Sigma), p-ATM(S1981) (Cell Signaling), 
p-p53(S15) (#9284 or #12571; Cell Signaling), Vinculin (hVin-1; Sigma), α-tubulin 
(B-5-1-2; Sigma), p21 (SXM30; BD Pharmingen), Puma (#7467; Cell Signaling), 
Arf (5-C3-1; Santa Cruz) and Cleaved Caspase-3(Asp175) (#9661; Cell 
Signaling).  For cycloheximide experiments, single cell suspensions of 
thymocytes from 6-8 thymi were generated maintained in DMEM supplemented 
with 10% FBS.  Thymocyte pools were untreated or irradiated with 2.5 Gy IR and 
immediately treated with cycloheximide (100 μg/ml; Sigma).  Pools were 
aliquoted and maintained in a 37°C incubator with 5% CO2 and collected for 
protein analysis at the indicated time points.  Blots were imaged on a Chemidoc 
MP (Bio-Rad) and relative band intensities determined by densitometry using 
Image Lab software (v4.1, Bio-Rad).    
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Gene Expression Analysis and Sequencing 
Total RNA was isolated from tissues by RNeasy mini kit (QIAGEN) and cDNA 
synthesized by Superscript III First Strand Synthesis System (oligo-dT priming) 
(Invitrogen).  Quantitative PCR was performed using SYBR Select Master Mix 
(Applied Biosystems) in conjunction with a 7300 Real-Time PCR System 
(Applied Biosystems).  Thymus cDNA input was 10 ng and bone marrow cDNA 
input was 100 ng.  Fold expression was calculated using the ΔΔCt method 
relative to untreated WT samples using Rplp0 as internal reference.  Primers 
used were as follows: Puma, 5’ACGACCTCAACGCGCAGTACG3’ and 
5’GAGGAGTCCCATGAAGAGATTG3’; Noxa, 
5’CTCAGGAAGATCGGAGACAAAG3’ and 5’GCACACTCGTCCTTCAAGT3’; 
Bax, 5’GTGGTTGCCCTCTTCTACTTT3’ and 5’CAGCCCATGATGGTTCTGAT3’; 
p21, 5’CTGAGCGGCCTGAAGATT3’ and 5’ATCTGCGCTTGGAGTGATAG3’; 
Mdm2, 5’AGTCTCTGGACTCGGAAGATTA3’ and 
5’CTGTATCGCTTTCTCCTGTCTG3’; Rplp0, 
5’CTGAGTACACCTTCCCACTTAC3’ and 5’CTCTTCCTTTGCTTCAGCTTTG3’.  
Arf message was amplified from tumor sample cDNA using the following primer 
pair: 5’TCGCTTGTCACAGTGAGG3’ and 5’CCGGATTTAGCTCTGCTCTT3’.  
p53 message was amplified from tumor sample cDNA in overlapping fragments 
using three separate primer pairs: p53seq1, 
5’TTCATTGGGACCATCCTGGCTGTA3’ and 
5’AGGCACAAACACGAACCTCAAAGC3’; p53seq2, 
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5’CTTATCCGGGTGGAAGGAAAT3’ and 5’GAAGTAGACTGGCCCTTCTTG3’; 
p53seq3, 5’AGCTTTGAGGTTCGTGTTTGTGCC3’ and 
5’ATGCAGACAGGCTTTGCAGAATGG3’.  Amplified fragments were gel 
extracted (QIAGEN) and sequenced by Sequegen, Inc (Worcester, MA).   
 
Histopathology  
Tissues samples were fixed in 10% formalin for 24 hr.  The UMMS Morphology 
Core Laboratory performed embedding, sectioning, and staining.  TUNEL 
staining was performed using the In Situ Cell Death Detection Kit, POD (Roche) 
according to manufacturer’s instructions.  Immunohistochemistry was performed 
with antibodies specific for B220 (550286; BD Pharmingen), CD3 (A0452; Dako) 
and TER-119 (553671; BD Pharmingen).  Stained tissue was analyzed using an 
Olympus CX41 microscope fitted with a PixeLINK camera and software. 
 
Flow Cytometry 
Total bone marrow from both hind limbs was harvested, RBCs were lysed, and 
single-cell suspensions were stained with cell-surface antibodies for Gr-1, 
CD11B, CD3, and B220.  For LSK analysis, bone marrow cells were stained with 
a biotin lineage mixture, and antibodies for Sca-1, c-Kit, CD34, and Flk2.  To 
distinguish between WT and Mdm2S394A hematopoietic cells in the reconstitution 
studies, peripheral blood and bone marrow was stained with antibodies specific 
for CD45.1 and CD45.2.  All samples were run on a BD LSRII flow cytometer (BD 
		
68	
Bioscience) and analyzed using FlowJo software (Tree Star).  A complete list of 
antibodies including clone numbers is given in Table 2.1.   
 
Table 2.1.  Antibodies Used for Flow Cytometry in Chapter II. 
Antibody Clone Fluorophore Source 
CD3 145-2C11 Biotin, APC BD Bioscience 
B220 RA3-6B2 Biotin, PE BD Bioscience 
Ter119 TER-119 Biotin Biolegend 
Gr-1 RB6-8C5 Biotin, APC, PE Biolegend 
Mac-1 M1/70 Biotin, FITC Biolegend 
Sca-1 D7 APC/Cy7 Biolegend 
CD117 2B8 APC BD Bioscience 
CD34 RAM34 FITC BD Bioscience 
Flk2 A2F10 PE Biolegend 
CD45.2 104 FITC, PE/Cy7 Biolegend 
CD45.1 A20 PercP/Cy5.5 Biolegend 
 
 
Statistical Analysis  
Statistical analyses were performed using GraphPad Prism software, version 
6.0d.  Kaplan–Meier survival curves were analyzed by log-rank test.  A P-value < 
0.05 was considered statistically significant for Student’s t-tests. 
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CHAPTER III 
Phosphorylation of Mdm2 by c-Abl regulates p53 tumor suppression and 
the radiosensitivity of mice. 
 
The p53 tumor suppressor acts as a guardian of the genome by 
preventing the propagation of DNA damage-induced breaks and mutations to 
subsequent generations of cells.  We have previously shown that ATM 
phosphorylation of Mdm2 Ser394 is required for robust p53 stabilization and 
activation in cells treated with ionizing radiation, and that inhibition of Mdm2 
Ser394 phosphorylation event leads to spontaneous tumorigenesis and 
radioresistance in Mdm2S394A mice.  Previous in vitro data indicate that the c-Abl 
kinase phosphorylates Mdm2 at the neighboring residue (Mdm2 Tyr393) in 
response to DNA damage to regulate p53-dependent apoptosis.  In this study, 
we have generated a novel Mdm2 mutant mouse (Mdm2Y393F) to determine if c-
Abl phosphorylation of Mdm2 regulates the p53-mediated DNA damage 
response or p53 tumor suppression in vivo.  Mdm2Y393F mice develop 
accelerated spontaneous and oncogene-induced tumors, yet display no defects 
in p53 stabilization and activity following acute genotoxic stress.  Although 
apoptosis is unaltered in these mice, they recover more rapidly from radiation-
induced bone marrow ablation, and are more resistant to whole body radiation-
induced lethality.  These data reveal an in vivo role for c-Abl phosphorylation of 
Mdm2 in regulation of p53 tumor suppression and bone marrow failure.  
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However, c-Abl phosphorylation of Mdm2-Y393 appears to play a lesser role in 
governing Mdm2-p53 signaling than ATM phosphorylation of Mdm2 Ser394.  
Furthermore, the effects of these phosphorylation events on p53 regulation are 
not additive, as Mdm2Y393F/S394A mice and Mdm2 S394A mice display similar 
phenotypes. 
 
Results 
Mdm2Y393F mice are viable and display increased spontaneous and 
oncogene-induced tumorigenesis.   
In order to investigate the role of Mdm2 Tyr393 phosphorylation under 
physiological conditions, we generated a mouse model in which this tyrosine 
residue is substituted with a phenylalanine residue (Y393F).  Site-directed 
mutagenesis was performed to introduce an A to T missense mutation within the 
393 codon, and a synonymous G to C mutation within the 397 codon of Mdm2 
exon 12 (Figure 3.1).   
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Figure 3.1.  Sequence of wild-type and mutant Mdm2 alleles surrounding 
codon 393.  DNA sequence of WT and Mdm2Y393F allele surrounding codon 393 
(top).  An A to T mutation changed codon 393 from Tyr to Phe.  A silent G to C 
mutation in codon 397 introduced a BtsCI restriction site.  Sequencing results of 
the corresponding region from Mdm2Y393F spleen cDNA are shown (bottom). 
 
A gene-replacement vector was constructed to replace the endogenous Mdm2 
exon 12 sequence with the mutated exon 12 (Figure 3.2).  Gene targeting was 
performed in PC3 (129SV) embryonic stem (ES) cells (O’Gorman et al., 1997), 
and homologous recombination was confirmed in G418-resistant clones by 
Southern blotting (Figures 3.2 and 3.3).  Blastocyst injection of targeted ES 
clones produced several high-degree male chimeras that passed the Mdm2 
Y393F allele through their germ line.  Southern blotting further confirmed proper 
targeting in F1 and F2 generation mice, along with protamine-Cre directed 
deletion of the floxed neomycin cassette (Figure 3.4).   
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Figure 3.2.  Diagram of the targeting strategy used to generate the 
Mdm2Y393F allele.  The targeting vector contained a floxed neomycin cassette 
(neo) and a 3’ thymidine kinase cassette (TK) for positive and negative drug 
selection, respectively.  The targeting vector was linearized and electroporated 
into PC3 ES cells.  ES cell targeting was confirmed by BamHI digest and 
Southern blot analysis with a 3’ external probe (green), as well as SpeI digest 
and Southern blot analysis with a 5’ external probe (blue).  Protamine-cre 
recombinase-directed excision of neo cassette was confirmed by BamHI digest 
of F1 and F2 generation tail DNA and Southern blot analysis with the same 3’ 
external probe as in ES cells (green). 
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Figure 3.3.  Southern blot analysis of targeted ES cells.  BamHI digest and 
Southern blot analysis of ES cell genomic DNA (left).  A 3’ external probe (green 
bar from Figure 3.2) detects a 9.7 kb WT allele and 3.8 kb targeted allele.  Four 
clones with correct 3’ targeting are shown, each flanked by untargeted (WT) 
clones.  SpeI digest and Southern blot analysis of ES cell genomic DNA (right).  
A 5’ external probe (blue bar from Figure 3.2) detects a 14.0 kb WT allele and 
10.4 kb targeted allele. 
 
 
 
 
Figure 3.4.  Southern blot analysis of mouse DNA.  BamHI digest and 
Southern blot analysis of tail DNA from F1 generation mice (left) and F2 
generation mice (right).  A 3’ external probe (green bar from Figure 3.2) detects a 
9.7 kb WT allele and 8.4 kb targeted allele.   
 
 
The presence of the additional synonymous G to C mutation within the 397 
codon of the targeted allele introduced a novel BtsCI restriction digest site that 
allowed for identification of the Mdm2Y393F allele by PCR-digest strategy (Figures 
3.1 and 3.5).  Mdm2 transcripts from spleens of Mdm2Y393F mice were 
sequenced, and confirmed as containing only the targeted mutations (Figure 
		
74	
3.1).  Heterozygous intercrosses yielded homozygous Mdm2Y393F mice at 
Mendelian ratios, indicating that Mdm2Y393F is not compromised in its function 
during development (Table 3.1).  Additionally, no differences were observed in 
average litter size, body weights at 6 weeks of age, or male-to-female sex 
distribution. 
 
      
Figure 3.5.  Genotyping Mdm2Y393F 
mice.  PCR-BtsCI digest analysis of F2 
generation mice.  Primers flanking 
Mdm2 codon 393 amplify a 436 bp 
fragment of DNA.  The WT Mdm2 
fragment contains a single BtsCI 
restriction site which generates 119 and 
317 bp fragments.  A silent mutation in 
the Mdm2Y393F allele introduces an 
additional BtsCI restriction site which 
results in 115, 119 and 202 bp 
fragments. 
Table 3.1.  Viability of 
Mdm2Y393F mice.  The expected 
and observed Mendelian ratios 
from Mdm2Y393F heterozygote 
breeding. 
 
 
 
 
 
 
 
 
 
We have previously shown that mice deficient for phosphorylation of the 
neighboring residue (Mdm2 Ser394) by the DNA damage activated kinase ATM 
are prone to spontaneous tumorigenesis (Gannon et al., 2012).  Therefore, we 
sought to examine whether c-Abl phosphorylation of Mdm2 Tyr393 impacted 
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tumor suppression.  Cohorts of WT and Mdm2Y393F mice were established and 
monitored for tumor formation.  During the 24-month tumor assay, 8 of 21 (38%) 
Mdm2Y393F mice developed spontaneous tumors (Figure 3.6), whereas only 1 of 
28 (4%) WT mice presented with a tumor at 20 months of age.  Mdm2Y393F 
tumors arose between 14.5-24 months of age, a similar latency as seen in 
Mdm2S394A mice (Gannon et al., 2012).  The majority of tumors arose in 
lymphatic tissues, and 5 of the 6 tumors (83%) were identified as B cell 
lymphomas, with one of the B cell lymphomas also containing atypical T cells.  
Other tumor types seen in the cohort included a myeloid sarcoma, a 
hepatocellular carcinoma, and a papillary tumor of lacrimal origin (Figures 3.7 
and 3.8, Table 3.2).   
 
 
 
Figure 3.6.  Spontaneous tumorigenesis 
in Mdm2Y393F mice.  Kaplan-Meier tumor-
free survival curves of WT (n = 28) and 
Mdm2Y393F (n = 21) mice.  Curves were 
compared by Log-rank test: (P < 0.01). 
 
 
 
Table 3.2.  Mdm2Y393F 
tumors.  Table displaying the 
latency, location, and tumor 
type for spontaneous tumors 
arising in Mdm2Y393F mice.  
LN, lymph node; HCC, 
hepatocellular carcinoma.
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Figure 3.7.  Mdm2Y393F tumor 
histology.  Representative H&E 
stained tissue sections of a lymph 
node exhibiting a B cell lymphoma 
(left) and myeloid sarcoma present in 
the liver sinusoids (right).  Scale bars 
represent 100μm.  LN, lymph node. 
 
Figure 3.8.  Mdm2Y393F tumor 
staining.  The B cell lymphomas 
shows expression of B220 (left), and 
the myeloid neoplasms exhibit 
naphtol chloroacetate esterase 
(NCA) staining (right).  Scale bars 
represent 100μm. 
 
 
As Mdm2Y393F mice were prone to developing spontaneous tumors of 
lymphoid origin, we further examined the effects of Mdm2 Tyr393 
phosphorylation on tumor suppression using the Eµ-myc mouse model (Adams 
et al., 1985).  Cohorts of Eµ-myc and Eµ-myc;Mdm2Y393F mice were generated 
(C57BL/6 background) and assayed for tumor formation.  Eµ-myc mice develop 
pre-B/B cell lymphomas within 3-6 months of age, and we observed a median 
time to tumorigenesis of 125.5 days in the Eµ-myc model cohort (Figure 3.9), a 
duration in close agreement with previous studies (Adams et al., 1985; Eischen 
et al., 1999).  However, Eµ-myc;Mdm2Y393F mice displayed significantly 
accelerated tumorigenesis, with a median time to tumor formation of only 76.5 
days.  Thus, while dispensable for development, c-Abl phosphorylation of Mdm2 
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Tyr393 significantly impacts tumor suppression by preventing both spontaneous 
and oncogene-induced tumorigenesis.   
 
 
Figure 3.9.  Eµ-myc-driven lymphomagenesis in Mdm2Y393F mice.  Kaplan-
Meier tumor-free survival curves of Eμ-myc (n = 16) and Eμ-myc;Mdm2Y393F (n = 
16) mice.  Median survival times were as follows: Eμ-myc (125.5 days), Eμ-
myc;Mdm2Y393F (76.5 days).  Curves were compared by Log-rank test: (P < 
0.0001). 
 
 
c-Abl phosphorylation of Mdm2 Tyr393 does not influence DNA damage-
induced p53 stabilization and activation in spleen and thymus. 
Having observed increased lymphomagenesis in Mdm2Y393F mice, and as 
c-Abl is activated by a variety of DNA damaging agents (Kharbanda et al., 1995; 
Liu et al., 1996; Wang et al., 2011a), we next examined whether c-Abl 
phosphorylation of Mdm2 Tyr393 impacts DNA damage-induced p53 stabilization 
and activation in lymphatic tissues of Mdm2Y393F mice.  WT and Mdm2Y393F mice 
were exposed to 5 Gy IR and spleens were analyzed for p53 and Mdm2 levels by 
immunoblotting (Figure 3.10).  We observed similar induction of p53 following 
irradiation in both genotypes, with no significant differences detected in basal or 
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IR-induced p53 protein levels.  Similarly, no obvious differences were observed 
in p53 activation as indicated by levels of p53 phosphorylation (S18).  No 
differences were observed in the levels of Mdm2 protein, which increased at 2-4 
hours following IR, before decreasing as p53 activity diminished, similar to what 
has previously been reported in this tissue (Gannon et al., 2012; Pant et al., 
2013).  Similar results were observed in thymi from these same animals, with no 
differences detected in the levels of total p53, phosphorylated p53 (S18), or 
Mdm2, save for slightly higher basal Mdm2 levels in Mdm2Y393F mice (Figure 
3.10).  Consistent with equal levels of basal and IR-induced p53 protein 
stabilization and phosphorylation, real-time quantitative PCR on cDNA from 
untreated and irradiated spleens of WT and Mdm2Y393F mice detected no 
differences in the basal or DNA damage-induced expression levels of the p53 
target genes Puma, Noxa, Cdkn1a (p21) and Mdm2 (Figure 3.11).  Similar 
results were observed in thymi (Figure 3.11).   
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Figure 3.10.  Western blots of irradiated spleens and thymi.  WT and 
Mdm2Y393F mice were left untreated or exposed to 5 Gy IR and spleens (left) and 
thymi (right) were harvested at 2 hour intervals.  Protein levels were analyzed by 
western blotting.  TKO indicates Mdm2 / , MdmX / , p53 /  control; Tg indicates 
Mdm2Tg/+ Mdm2 overexpressing control. 
 
Figure 3.11.  Gene expression in irradiated spleens and thymi.  Mice were 
left untreated or exposed to 5 Gy IR and spleens (top) and thymi (bottom) were 
harvested at 4 hours.  Fold expression of p53-target genes was determined by 
real-time quantitative PCR, relative to untreated WT samples using Rplp0 as 
internal reference (n = 3-4, ±SEM).  Significance was determined by Student’s t-
test of ΔΔCt values. 
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Hematopoietic organs are highly radiosensitive, and p53 activation in 
these tissues prompts widespread apoptosis following IR (Gudkov and 
Komarova, 2003).  In keeping with the absence of observable differences in p53 
stabilization and activation in Mdm2Y393F spleens and thymi, we detected no 
differences in splenic or thymic apoptosis in untreated and irradiated Mdm2Y393F 
mice by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 
(Figure 3.12).  This observation was confirmed quantitatively by flow cytometry of 
Annexin V-FITC stained splenocytes and thymocytes (Figure 3.13).  Thus, the 
IR-induced stabilization and activation of p53 and the resultant apoptotic 
response is unaltered in Mdm2Y393F spleens and thymi. 
 
 
Figure 3.12.  Apoptosis in irradiated spleens and thymi.  TUNEL staining of 
spleens of mice treated as in Figure 3.10 and harvested at 3 and 6 hours. 
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Figure 3.13.  Quantification of apoptosis in irradiated spleens and thymi.  
WT, Mdm2Y393F and p53 /  mice were left untreated or irradiated with 5 Gy IR.  
Spleens or thymi were harvested 5 hours later and single cell suspensions of 
splenocytes (left) or thymocytes (right) were generated and stained with Annexin 
V-FITC and propidium iodide (PI) for FACS analysis.  The percentage of Annexin 
VH gh - PILow cells were quantified (n = 3, ±SEM).  Significance was determined 
relative to similarly treated WT samples, **P < 0.01 (Student’s t-tests). 
 
We also examined whether Mdm2 Tyr393 phosphorylation affected p53-
dependent growth arrest.  Mouse embryonic fibroblasts (MEFs) from WT, 
Mdm2Y393F and p53 /  mice were untreated or exposed to either 5 Gy IR or 150 
nM doxorubicin for 18 hours.  Flow cytometric cell cycle analysis of these cells 
revealed no differences in growth arrest in Mdm2Y393F MEFs following either 
irradiation or treatment with doxorubicin (Figure 3.14).  Furthermore, no 
differences were observed in the cell cycle populations of untreated WT and 
Mdm2Y393F MEFs (data not shown).  This indicated that WT and Mdm2Y393F MEFs 
exhibit similar growth rates, and was confirmed by standard proliferation assays 
(Figure 3.15).   
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Figure 3.14.  Cell-cycle arrest in 
MEFs.  MEFs untreated or exposed 
to 4 Gy IR (left) or 200 nM 
doxorubicin (right) for 18 hours, were 
pulse labeled with 50 µM BrdU for 3 
hrs, harvested and fixed for FACS 
analysis.  Fixed cells were stained 
with a FITC conjugated anti-BrdU 
antibody and PI, and analyzed by 
flow cytometry.  Data are presented 
as the percentage of cells in S phase 
in the treated samples relative to 
untreated samples (n = 3, ±SEM).  
**P < 0.01 (Student’s t-tests). 
Figure 3.15.  Primary MEF 
proliferation.  106 cells were seeded 
in 6-well plates and cell number per 
well was counted each day (n = 3, 
±SD). 
 
 
 
 
 
 
 
 
 
Mdm2Y393F mice are radioresistant and display enhanced bone marrow 
repopulating abilities following IR exposure.   
The proposed effects of c-Abl phosphorylation of Mdm2 on p53 are similar 
to those of ATM phosphorylation of Mdm2, namely p53 stabilization and 
activation.  Conversely, our findings that DNA damage-induced p53 stabilization 
and activation in spleen and thymus, and p53-dependent apoptosis and growth 
arrest in Mdm2Y393F tissues and cells, are unaltered, contrasts with what we have 
reported with Mdm2S394A mice.  Thus, c-Abl phosphorylation of Mdm2 Tyr393 
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may have limited effects on the p53-dependent DDR in vivo, or may be 
adequately compensated for by ATM phosphorylation of Mdm2 Ser394.  
However, when we challenged cohorts of WT and Mdm2Y393F mice to a series of 
IR doses spanning the threshold-lethal range, we observed a significant 
resistance to whole-body IR-induced lethality in Mdm2Y393F mice (Figure 3.16).  
Following treatment with 8 Gy IR, 74% of Mdm2Y393F mice were surviving at 4 
weeks as compared to 22% of WT mice.  Similarly, following exposure to 9 Gy 
IR, 29% of Mdm2Y393F mice were surviving at 4 weeks as compared to 7% of WT 
mice.  All mice survived 7 Gy IR for both genotypes, whereas no mice of either 
genotype survived past 2 weeks following 10 Gy IR.  The majority of mice 
succumbed between one and three weeks post-IR.   
 
 
Figure 3.16.  Radioresistance in Mdm2Y393F mice.  Kaplan-Meier survival 
curves of WT (n = 7-18) and Mdm2Y393F (n = 6-19) mice exposed to 7, 8, 9 and 
10 Gy whole-body IR.  WT and Mdm2Y393F curves were compared by Log-rank 
test: 7 Gy (n.s.), 8 Gy (P = 0.003), 9 Gy (P = 0.030), 10 Gy (n.s.). 
 
Lethality in mice treated with this range of IR doses is attributed to p53-
dependent bone marrow failure, referred to as ‘hematopoietic syndrome’ 
(Komarova et al., 2004).  As we have described a similar resistance to whole-
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body IR in Mdm2S394A mice (Gannon et al., 2012), we next compared the effects 
of IR on bone marrow from WT, Mdm2Y393F, Mdm2S394A and p53 /  mice.  
Expression of p53 target genes Puma and p21 are unaltered in Mdm2Y393F bone 
marrow, in agreement with what was observed in irradiated spleen and thymus 
(Figure 3.17).  Conversely, expression levels of those same genes are 
significantly reduced in Mdm2S394A bone marrow, in keeping with the previously 
described reduction in IR-induced p53 responses in these animals (Gannon et al, 
2012).   
 
 
Figure 3.17.  Gene expression in bone marrow.  Fold expression of p53-target 
genes Puma, Noxa and p21 in bone marrow of WT, Mdm2Y393F, Mdm2S394A and 
p53 /  mice, untreated and 6 hours after 5 Gy IR, was determined by real-time 
quantitative PCR.  Fold expression was calculated relative to untreated WT 
samples using Rplp0 as internal reference (n = 3-4 mice, ±SEM).  *P < 0.05, **P 
< 0.01 (Student’s t-tests of ΔΔCt values). 
 
However, similar initial reductions in bone marrow cellularity were observed in 
both mutants, as well as in WT mice and in p53 /  mice following treatment with 5 
Gy IR (Figure 3.18).  Thus, the initial reduction in gross cellularity appears, to 
some extent, independent of p53.  Flow cytometry analysis of untreated bone 
marrow from WT, Mdm2Y393F, Mdm2S394A and p53 /  mice revealed no differences 
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in the populations of lineage-defined, mature hematopoietic cells, save for 
statistically fewer CD11b-positive cells in p53 /  mice (Figure 3.19, top).  In 
agreement with the observed reduction in bone marrow cellularity in all 
genotypes, IR treatment induced a cumulative decline in populations of mature 
cells in bone marrow from each genotype (Figure 3.19, bottom).  Only p53 /  mice 
displayed significantly more B220+ cells.   
 
 
Figure 3.18.  Relative bone marrow cellularity.  
Quantification of numbers of nucleated cells in bone 
marrow from both hind limbs of WT, Mdm2Y393F, 
Mdm2S394A and p53 /  mice either untreated or 8 hours 
after exposure to 5 Gy IR.  (n = 3-6, ±SEM). 
 
 
Figure 3.19.  Quantification of lineage-defined hematopoietic cells in bone 
marrow.   
Quantification of Lineage-defined hematopoietic cells in bone marrow of WT, 
Mdm2Y393F, Mdm2S394A and p53 /  mice untreated (left) and 8 hours after 5 Gy IR 
(right) (n = 3-4, ±SEM).  **P < 0.01 (Student’s t-tests). 
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Again, no differences were observed in the absence of treatment, in the more 
primitive Lin−Sca1−cKit+ (L−S−K) progenitor populations of WT, Mdm2Y393F, 
Mdm2S394A or p53 /  mice (Figure 3.20).  However, while L−S−K cell numbers 
decreased 70-80% in WT, Mdm2Y393F and Mdm2S394A bone marrows, bone 
marrow from p53 /  mice retained significantly more L−S−K cells following IR.  This 
suggests that increased survival of hematopoietic progenitors underlies the 
resistance to IR-induced bone marrow failure in mice with compromised p53.  
Indeed, when Lin−Sca1+cKit+ (L−SK) hematopoietic stem and progenitor cells 
(HSPCs) were quantified in these same animals, we observed no decrease 
following irradiation in p53 /  mice (Figure 3.21).  While greater numbers of 
HSPCs were observed in untreated p53 /  mice, no differences were observed in 
HSPC number in untreated WT, Mdm2Y393F and Mdm2S394A mice.  However, 
there were significantly more HSPCs in Mdm2S394A bone marrow following IR, 
and HSPC levels also appeared slightly (though not statistically) elevated in 
irradiated Mdm2Y393F bone marrow.   
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Figure 3.20.  Quantification of L S
K hematopoietic progenitor cells 
in bone marrow.  Quantification of 
L S K hematopoietic progenitor cells 
in bone marrow of WT, Mdm2Y393F, 
Mdm2S394A and p53 /  mice, either 
untreated or 8 hours after 5 Gy IR (n 
= 3-4, ±SEM).  **P < 0.01 (Student’s 
t-tests). 
Figure 3.21.  Quantification of L
SK hematopoietic progenitor cells 
in bone marrow.  Quantification of 
L SK (HSPC) hematopoietic 
progenitor cells in bone marrow of 
WT, Mdm2Y393F, Mdm2S394A and p53
/  mice treated as described in (B).  
*P < 0.05, **P < 0.01 (Student’s t-
tests). 
 
 
 
We examined whether the resistance to acute whole-body IR-associated lethality 
observed in Mdm2Y393F and Mdm2S394A mice was due to an increased capacity to 
repopulate irradiated marrow by performing haematoxylin and eosin (H&E) stains 
on bone marrow from mice either untreated or 6 and 9 days following 8 Gy IR 
(Figure 3.22).  At 6 days post-IR, while mice of all three genotypes displayed 
evidence of a significant decrease in cellularity, both p53 / and Mdm2S394A bone 
marrow, and to a lesser extent Mdm2Y393F bone marrow, contained multiple 
colonies of hematopoietic cells that were not apparent in WT bone marrow, as 
well as visibly more erythrocytes.  By 9 days post-IR, coinciding with the period of 
observed morbidity in threshold-lethally irradiated animals, an even larger 
discrepancy in cellularity was observable between WT and mutant bone 
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marrows.  Few hematopoietic colonies were visible in WT marrow, while colonies 
present in p53 / and Mdm2S394A mice had expanded significantly and largely 
replenished the medullary cavity.  While there was greater visible repopulation in 
Mdm2Y393F bone marrow as compared to WT, this repopulation appeared 
intermediate to that observed in Mdm2S394A bone marrow, trending with the 
observed improved HSPC survival following IR. 
 
 
Figure 3.22.  Haematoxylin and eosin stained bone marrow following IR.  
Haematoxylin and eosin stained bone marrow from WT, Mdm2Y393F, Mdm2S394A 
and p53 /  mice exposed to 8Gy IR.  Scale bars represent 100μm. 
 
Mdm2 Tyr393 and Ser394 phosphorylations are not additive in their impact 
on tumor suppression and radioresistance. 
To determine whether the shared effects of Mdm2 Tyr393 and Ser394 
phosphorylation were redundant or additive, we generated a knock-in mouse in 
which both the Tyr393 residue is substituted with a phenylalanine residue 
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(Y393F) and the Ser394 residue is substituted with an alanine (S394A) (Figure 
3.23).  Gene targeting was carried out following a similar strategy as utilized for 
Mdm2Y393F mice (Figures 3.24-3.27).  The targeting construct coded for an A to T 
missense mutation within the 393 codon, a T to G missense mutation within the 
394 codon, and a synonymous T to G mutation within the 398 codon of Mdm2 
exon 12, which also permitted PCR-digest genotyping of cells and mice.  As 
observed for Mdm2S394A mice (Gannon et al., 2012), Mdm2Y393F/S394A mice were 
recovered from heterozygous intercrosses at Mendelian ratios (Table 3.3).   
 
 
 
Figure 3.23.  Sequence of wild-type and mutant Mdm2 alleles surrounding 
codons 393 and 394.  DNA sequence of WT and Mdm2Y393F/S394A allele 
surrounding codons 393 and 394 (top).  An A to T mutation changed codon 393 
from Tyr to Phe.  A T to C mutation changed codon 394 from Ser to Ala.  A silent 
T to G mutation in codon 398 introduced a AatII restriction site.  Sequencing 
results of the corresponding region from Mdm2Y393F/S394A spleen cDNA are shown 
(bottom). 
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Figure 3.24.  Diagram of the targeting strategy used to generate the 
Mdm2Y393F/S394A allele.  The targeting vector contained a floxed neomycin 
cassette (neo) and a 3’ thymidine kinase cassette (TK) for positive and negative 
drug selection, respectively.  The targeting vector was linearized and 
electroporated into PC3 ES cells.  ES cell targeting was confirmed by BamHI 
digest and Southern blot analysis with a 3’ external probe (green), as well as 
SpeI digest and Southern blot analysis with a 5’ external probe (blue).  
Protamine-Cre recombinase-directed excision of neo cassette was confirmed by 
BamHI digest of F1 generation tail DNA and Southern blot analysis with the 
same 3’ external probe as in ES cells (green). 
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Figure 3.25.  Southern blot analysis 
of targeted ES cells.  BamHI digest 
and Southern blot analysis of ES cell 
genomic DNA (left).  A 3’ external probe 
(green bar from Figure 3.24) detects a 
9.7 kb WT allele and 3.8 kb targeted 
allele.  Two clones with correct 3’ 
targeting are shown, each flanked by 
untargeted (WT) clones.  SpeI digest 
and Southern blot analysis of ES cell 
genomic DNA (right).  A 5’ external 
probe (blue bar from Figure 3.24) 
detects a 14.0 kb WT allele and 10.4 kb 
targeted allele.   
 
Figure 3.26.  Southern blot 
analysis of mouse DNA.  
BamHI digest and Southern blot 
analysis of tail DNA from F1 
generation mice.  A 3’ external 
probe (green bar from Figure 
3.24) detects a 9.7 kb WT allele 
and 8.4 kb targeted allele. 
 
 
 
 
 
 
  
 
 
Figure 3.27.  Genotyping Mdm2Y393F/S394A 
mice.  PCR-BtsCI digest analysis of F2 
generation mice.  Primers flanking Mdm2 
codons 393 and 394 amplify a 436 bp 
fragment of DNA.  A silent mutation in the 
Mdm2Y393F/S394A allele introduces a novel 
AatII restriction site which results in 193 
and 243 bp fragments. 
Table 3.3.  Viability of 
Mdm2Y393F/S394A mice.  The 
expected and observed 
Mendelian ratios from 
Mdm2Y393F/S394A heterozygote 
breeding. 
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A cohort of bi-allelic Mdm2Y393F/S394A mice were monitored for spontaneous tumor 
presentation, and by 24 months, 14 of 21 (67%) of these mice presented with 
tumors (Figure 3.28).  This mirrors the 65% of Mdm2S394A mice that developed 
spontaneous tumors in our previous study (Gannon et al., 2012), as does the 
observed latency of 18-24 months for the majority of tumors.  Consequently, the 
tumor suppressive effects of Mdm2 Tyr393 phosphorylation by c-Abl and Mdm2 
Ser394 phosphorylation by ATM do not appear to be synergistic.  The 
predominant tumor type in Mdm2Y393F/S394A mice was B cell lymphoma (6/15, 
40%), along with myeloid sarcoma/lymphomas (5/15, 33%), hepatocellular 
carcinomas (3/15, 20%), and one tumor which appeared to be a liver metastasis 
of neuroendocrine cell origin (Table 3.4, Figures 3.29 and 3.30).   
 
 
Figure 3.28.  Spontaneous tumorigenesis in Mdm2Y393F/S394A mice.  Kaplan-
Meier tumor-free survival curve of Mdm2Y393F/S394A mice (n = 21).  Included are 
tumor-free survival curves of WT and Mdm2Y393F mice described in Figure 3.6, 
and Mdm2S394A mice described previously (Gannon et al., 2012).  Curves were 
compared by Log-rank test: Mdm2Y393F/S394A to WT (P < 0.0001), Mdm2Y393F/S394A 
to Mdm2Y393F (P = 0.080). 
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Table 3.4.  Mdm2Y393F/S394A tumors.  Table displaying the latency, location, and 
tumor type for spontaneous tumors arising in Mdm2Y393F/S394A mice. 
 
 
 
 
Figure 3.29.  Mdm2Y393F/S394A tumor 
histology.  Representative H&E stained 
tissue sections of a B cell lymphoma (left), 
myeloid sarcoma (middle) and hepatoma 
(right) that developed in Mdm2Y393F/S394A 
mice.  Scale bars represent 100μm. 
 
Figure 3.30.  Mdm2Y393F/S394A 
tumor staining.  B cell 
lymphoma shows expression 
of B220 as detected by IHC 
(left), and a myeloid neoplasm 
exhibits NCA activity (right).  
Scale bars represent 100μm.
Irradiated thymi from Mdm2Y393F/S394A mice were examined by 
immunoblotting, as well as by qPCR of p53 target gene transcripts, and showed 
a similar reduction of p53 stabilization and activity as observed in Mdm2S394A 
mice (Figures 3.31 and 3.32).  This is in keeping with the absence of observable 
defects in the p53 response to DNA damage in Mdm2Y393F mice described in 
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Figures 3.10-3.13.  Accordingly, while reduced in comparison to WT, no 
additional deficits in apoptosis were observed by TUNEL staining or Annexin V 
staining followed by flow cytometry of Mdm2Y393F/S394A thymi relative to those 
seen in Mdm2S394A thymi (Figures 3.33 and 3.34).   
 
 
Figure 3.31.  Western blots of irradiated Mdm2 mutant thymi.  WT and 
Mdm2S394A mice (left) or Mdm2Y393F/S394A mice (right) were left untreated or 
exposed to 5 Gy IR and thymi were harvested at 2 hour intervals.  Protein levels 
were analyzed by western blotting.  TKO indicates Mdm2 / , MdmX / , p53 /  
control; Tg indicates Mdm2Tg/+ Mdm2 overexpressing control. 
 
 
 
Figure 3.32.  Gene expression in irradiated Mdm2 mutant thymi.  WT, 
Mdm2Y393F, Mdm2S394A, Mdm2Y393F/S394A and p53 /  mice were left untreated or 
exposed to 5 Gy IR and thymi were harvested at 4 hours.  Fold expression of 
p53-target genes was determined by real-time quantitative PCR, relative to 
untreated WT samples using Rplp0 as internal reference (n = 3-4, ±SEM).  *P < 
0.05, **P < 0.01 (Student’s t-tests of ΔΔCt values). 
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Figure 3.33.  Apoptosis in 
irradiated Mdm2 mutant thymi.  
TUNEL staining of thymi from 
WT, Mdm2S394A, Mdm2Y393F/S394A 
and p53 /  mice treated with 5 Gy 
IR and harvested at 3 and 6 
hours. 
 
 
 
 
 
 
 
 
 
 
Figure 3.34.  Quantification of 
apoptotic Mdm2 mutant thymocytes.  
Thymi were harvested from WT, 
Mdm2Y393F, Mdm2S394A, Mdm2Y393F/S394A 
and p53 /  mice 5 hours after treatment 
with 5 Gy IR and thymocytes were 
stained with AnnexinV-FITC and 
propidium iodide (PI) for FACS analysis 
(top).  The percentage of Annexin VH gh - 
PILow cells were quantified (n = 3, 
±SEM).  **P < 0.01 (Student’s t-tests).  
Protein lysates generated from fractions 
of WT, Mdm2Y393F, Mdm2S394A and 
Mdm2Y393F/S394A cell suspensions were 
analyzed for p53 and p-p53 (S18) 
protein levels  (bottom).
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Finally, we examined whether the radioresistant phenotypes observed in 
Mdm2Y393F and Mdm2S394A mice were exacerbated in Mdm2Y393F/S394A mice.  
Mdm2S394A and Mdm2Y393F/S394A mice were exposed to 9Gy whole-body IR (as 
utilized for Mdm2Y393F mice) and monitored for signs of morbidity (Figure 3.35).  
No significant difference in survival was observed between Mdm2S394A and 
Mdm2Y393F/S394A mice at this dose, with 82% of Mdm2S394A mice and 69% of 
Mdm2Y393F/S394A mice surviving at 4 weeks, respectively.   
 
Figure 3.35.  Radioresistance in Mdm2 mutant mice.  Kaplan-Meier survival 
curves of WT (n = 15), Mdm2Y393F (n = 17), Mdm2S394A (n = 11), and 
Mdm2Y393F/S394A (n = 13) mice exposed to 9 Gy whole-body IR.  Curves were 
compared by Log-rank test: WT to Mdm2Y393F (P = 0.030), WT to Mdm2S394A (P < 
0.0001), WT to Mdm2Y393F/S394A (P < 0.0001), Mdm2Y393F to Mdm2S394A (P = 
0.010), Mdm2Y393F to Mdm2Y393F/S394A (P = 0.020), Mdm2S394A to Mdm2Y393F/S394A 
(n.s.). 
 
However, both genotypes are significantly more radioresistant than Mdm2Y393F 
mice, which are themselves significantly more radioresistant than WT mice at this 
dose.  Thus, radioresistance resulting from the loss of either Mdm2 Tyr393 
phosphorylation by c-Abl or Mdm2 Ser394 phosphoylation by ATM is not 
additive.  Accordingly, IR-induced expression levels of p53 target genes in 
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irradiated bone marrow of Mdm2S394A and Mdm2Y393F/S394A mice are similarly 
reduced (Figure 3.36).  The equivalent deficiency in the p53 response in 
Mdm2S394A and Mdm2Y393F/S394A bone marrow follows with comparably increased 
numbers of L−SK HSPCs surviving in Mdm2Y393F/S394A bone marrow following IR 
(Figure 3.37).  Furthermore, bone marrow cells from Mdm2Y393F/S394A or 
Mdm2S394A mice exhibit similar hematopoietic repopulating abilities in vivo (Figure 
3.38).  As was observed with Mdm2Y393F and Mdm2S394A mice, no differences 
were seen in the number of lineage-defined or L−S−K hematopoietic cells 
(Figures 3.39 and 3.40). 
 
 
 
Figure 3.36.  Gene expression in irradiated Mdm2 mutant bone marrow.  
Fold expression of p53-target genes in bone marrow of WT, Mdm2Y393F, 
Mdm2S394A and p53 /  mice, as shown in Figure 3.17, untreated and 6 hours after 
5 Gy IR, including expression data from Mdm2Y393F/S394A bone marrow.  (n = 3-4 
mice, ±SEM).  No significant difference is observed between Mdm2S394A and 
Mdm2Y393F/S394A expression levels (Student’s t-tests of ΔΔCt values). 
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Figure 3.37.  Quantification of L
SK hematopoietic progenitor cells 
in Mdm2 mutant bone marrow.  
Bone marrow was harvested from 
mice untreated or 8 hours following 5 
Gy IR (n = 3-6, ±SEM).  **P < 0.01 
(Student’s t-tests). 
Figure 3.38.  Haematoxylin and 
eosin stained Mdm2S394A and 
Mdm2Y393F/S394A bone marrow.  
Mice were exposed to 8Gy IR.  Scale 
bars represent 100μm.
 
 
 
 
Figure 3.39.  Quantification of lineage-defined hematopoietic cells in Mdm2 
mutant bone marrow.  Untreated bone marrow (top) or 8 hours after 5 Gy IR 
(bottom) from WT, Mdm2Y393F, Mdm2S394A and p53 /  mice, as shown in Figure 
3.19, including data from Mdm2Y393F/S394A bone marrow (n = 3-4, ±SEM).  No 
significant difference is observed between Mdm2S394A and Mdm2Y393F/S394A 
lineage-defined cell numbers (Student’s t-tests). 
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Figure 3.40.  Quantification of L S K hematopoietic progenitor cells in 
Mdm2 mutant bone marrow.  Bone marrow from WT, Mdm2Y393F, Mdm2S394A 
and p53 /  mice, as shown in Figure 3.20, either untreated or 8 hours after 5 Gy 
IR, including data from Mdm2Y393F/S394A bone marrow (n = 3-4, ±SEM).  No 
significant difference is observed between Mdm2S394A and Mdm2Y393F/S394A L S K 
progenitor cell numbers (Student’s t-tests). 
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Materials and Methods 
Mice and Animal Studies 
All animals described in this study were on a C57Bl/6 background.  Mice and 
cells were irradiated with a cesium-137 source (Gammacell 40).  The generation 
of Mdm2S394A mice has been previously described (Gannon et al, 2012).  Eμ-myc 
mice were a gift from Christine Eischen (Vanderbilt University).  A detailed 
description of the generation and genotyping of Mdm2Y393F and Mdm2Y393F/S394A 
mice is provided below.  All animals used in this study were maintained and 
assayed in accordance with federal guidelines and those established by the 
Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School. 
 
Generation and Genotyping of Mdm2Y393F and Mdm2Y393F/S394A Mice  
Targeting vectors were constructed from subcloned fragments of the Mdm2 
genomic sequence (129Sv strain).  Site-directed mutagenesis was performed 
according to manufacturer instructions using a QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene).  Targeting vectors were sequenced to ensure only 
the desired mutations were introduced.  Linearized targeting vectors were 
introduced into PC3 ES cells by electroporation.  Targeted homologous 
recombination was detected by Southern blotting using 5’ and 3’ external probes 
after SpeI and BamHI restriction digests, respectively.  Targeted cells were 
microinjected into E3.5 blastocysts (C57BL/6 strain), and embryos were 
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surgically implanted into pseudopregnant foster mice by standard procedures.  
Transmission of the knock-in allele and excision of the neo cassette in F1 and F2 
offspring of male chimeric mice was confirmed by Southern blotting using the 
same 3’ external probe and BamHI restriction digest strategy as in ES cells.  
Mdm2Y393F and Mdm2Y393F/S394A alleles were followed by genomic PCR using the 
primer pair: Forward 5’AAAGATGCTGGACCCTTCGTGAGA3’ and Reverse 
5’GCACACGTGAAACATGACATGAGG3’, followed by BtsCI digest to identify the 
Mdm2Y393F allele or AatII digest to identify the Mdm2Y393F/S394A allele. 
 
Immunoblotting 
Tissues and cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 
mM NaCl, 0.5% NP-40) supplemented with protease and phosphatase inhibitor 
cocktail tablets (Roche).  Protein extracts (50 µg) were analyzed by direct 
western blotting with antibodies specific for Mdm2 (NBP1-02158; Novus), p53 
(CM5; Novocastra), p-p53(S15) (#9284; Cell Signaling), α-tubulin (B-5-1-2; 
Sigma), Vinculin (hVin-1; Sigma) and PI3K p85 (06-496; Millipore).  Blots were 
imaged on a Chemidoc MP (Bio-Rad) and relative band intensities determined by 
densitometry using Image Lab software (v4.1, Bio-Rad). 
 
Quantification of Apoptosis  
Animals were treated as described.  Thymi and spleens were harvested and 
single cell suspensions generated by mechanical disruption and screening 
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through 70 µm mesh.  Red blood cells were lysed in splenocyte samples by 
suspension in ammonium-chloride-potassium (ACK) buffer.  Samples were 
stained using an Annexin V-FITC Apoptosis Detection Kit I (BD Pharmingen 
#556547) according to manufacturer protocol.  Flow cytometry was performed by 
the UMASS Medical School Flow Cytometry Core Lab.  Early apoptotic cells 
(Annexin Vh gh PI ow) were quantified using FlowJo software (Tree Star).    
 
Cell Cycle Analysis 
Treated MEFs were pulse labeled with 50µM bromodeoxyuridine (BrdU) for 3 
hours before being harvested by trypsinization and fixed in 70% ethanol 
overnight.  Fixed cells were stained with FITC conjugated anti-BrdU antibody 
(Becton Dickinson #347583) and PI, and analyzed by flow cytometry by the 
UMASS Medical School Flow Cytometry Core Lab.  Cell cycle populations were 
quantified using FlowJo software (Tree Star). 
 
Gene Expression Analysis and Sequencing 
Total RNA was isolated from tissues by RNeasy mini kit (QIAGEN) and cDNA 
synthesized by Superscript III First Strand Synthesis System (oligo-dT priming) 
(Invitrogen).  Quantitative PCR was performed using SYBR Select Master Mix 
(Applied Biosystems) in conjunction with a 7300 Real-Time PCR System 
(Applied Biosystems).  Thymus cDNA input was 10 ng and bone marrow cDNA 
input was 100 ng.  Fold expression was calculated using the ΔΔCt method 
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relative to untreated WT samples using Rplp0 as internal reference.  Primers 
used were as follows: Puma, 5’ACGACCTCAACGCGCAGTACG3’ and 
5’GAGGAGTCCCATGAAGAGATTG3’; Noxa, 
5’CTCAGGAAGATCGGAGACAAAG3’ and 5’GCACACTCGTCCTTCAAGT3’; 
p21, 5’CTGAGCGGCCTGAAGATT3’ and 5’ATCTGCGCTTGGAGTGATAG3’; 
Mdm2, 5’AGTCTCTGGACTCGGAAGATTA3’ and 
5’CTGTATCGCTTTCTCCTGTCTG3’; Rplp0, 
5’CTGAGTACACCTTCCCACTTAC3’ and 5’CTCTTCCTTTGCTTCAGCTTTG3’.  
Mdm2 message was amplified from spleen cDNA in overlapping fragments using 
two separate primer pairs: Mdm2seq1, 5’CCAGGCCAATGTGCAATACCAACA3’ 
and 5’TCCTCAGCACATGGCTCTTTAGCA3’; Mdm2seq2, 
5’TCTTGACGATGGCGTAAGTGAGCA3’ and 
5’TCCAAAGTCCTTCCAAGCGGAGAT3’.  Amplified fragments were gel 
extracted (QIAGEN) and sequenced by Sequegen, Inc (Worcester, MA). 
 
Histopathology  
Tissues samples were fixed in 10% formalin for 24 hr.  The UMMS Morphology 
Core Laboratory performed embedding, sectioning, and staining.  TUNEL 
staining was performed using the In Situ Cell Death Detection Kit, POD (Roche) 
according to manufacturer’s instructions.  Immunohistochemistry was performed 
with antibodies specific for B220 (550286; BD Pharmingen) and CD3 (A0452; 
Dako).  Napthol chloroacetate esterase staining (Leder Stain) was performed to 
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detect cells with myeloid differentiation.  Stained tissue was analyzed using an 
Olympus CX41 microscope fitted with a PixeLINK camera and software. 
 
Bone Marrow Analysis 
Total bone marrow from both hind limbs was harvested, RBCs were lysed, and 
single-cell suspensions were stained with cell-surface antibodies for Gr-1, 
CD11B, CD3, and B220.  For LSK analysis, bone marrow cells were stained with 
a biotin lineage mixture, and antibodies for Sca-1, c-Kit, CD34, and Flk2.  All 
samples were run on a BD LSRII flow cytometer (BD Bioscience) and analyzed 
using FlowJo software (Tree Star).  A complete list of antibodies including clone 
numbers is given in Table 3.5.   
 
Table 3.5.  Antibodies used for flow cytometry in Chapter III 
Antibody Clone Fluorophore Source 
CD3 145-2C11 Biotin, APC BD Bioscience 
B220 RA3-6B2 Biotin, PE BD Bioscience 
Ter119 TER-119 Biotin Biolegend 
Gr-1 RB6-8C5 Biotin, APC, PE Biolegend 
Mac-1 M1/70 Biotin, FITC Biolegend 
Sca-1 D7 APC/Cy7 Biolegend 
CD117 2B8 APC BD Bioscience 
CD34 RAM34 FITC BD Bioscience 
Flk2 A2F10 PE Biolegend 
CD45.2 104 FITC, PE/Cy7 Biolegend 
CD45.1 A20 PercP/Cy5.5 Biolegend 
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Statistical Analysis  
Statistical analyses were performed using GraphPad Prism software, version 
6.0d.  Kaplan–Meier survival curves were analyzed by log-rank test.  A P-value < 
0.05 was considered statistically significant for Student’s t-tests. 
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CHAPTER IV 
Discussion 
 
In response to DNA damage, numerous kinases become activated and 
phosphorylate various proteins involved in the DNA damage response, including 
the p53 tumor suppressor protein and its chief negative regulator, Mdm2.  These 
signaling events have been proposed by many groups to activate p53 by 
interrupting Mdm2-inhibition of p53, thereby facilitating p53 transactivation of 
downstream target genes whose products regulate the cellular response to DNA 
damage.  Previously, our lab and others have shown that phosphorylation of p53 
following DNA damage has only a modest role in regulating p53 stabilization and 
activation, p53-mediated apoptosis and governing p53 tumor suppression in vivo 
(Wu et al., 2002; Chao et al., 2003; Sluss et al., 2004; MacPherson et al., 2004; 
Chao et al., 2006).  However, having generated Mdm2S394A knock-in mice, our 
lab has shown that ATM phosphorylation of Mdm2 Ser394 significantly regulates 
the amplitude and duration of the p53 response to DNA damage in mice, and 
alters p53 suppression of spontaneous tumorigenesis (Gannon et al., 2012).  
These studies demonstrate the in vivo importance of Mdm2 phosphorylation in 
the regulation of the p53 DNA damage response.  
In Chapter II of this dissertation, we explore in vivo the mechanism by 
which Mdm2 Ser394 phosphorylation alters p53 functions, and examine whether 
ATM-Mdm2-p53 signaling regulates tumorigenesis in mice induced by activated 
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oncogenes or ionizing radiation.  Our results indicate that Mdm2 Ser394 
phosphorylation regulates Mdm2 stability and has dramatically different and 
stress-dependent effects in tumorigenesis, suppressing Myc-driven 
lymphomagenesis and promoting IR-induced lymphomagenesis.  In Chapter III 
we present a novel knock-in mouse that cannot be phosphorylated at Mdm2 
Tyr393 by c-Abl (Mdm2Y393F mice).  The study of these mice provides further 
evidence of the significance of Mdm2 phosphorylation by DNA damage activated 
kinases in regulating p53 dependent organismal responses.  Though we 
observed no defects in the acute DNA damage-induced stabilization and 
activation of p53 in Mdm2Y393F mice, they display increased spontaneous and 
oncogene-induced tumorigenesis and radioresistance.  We also present a mouse 
model in which both the c-Abl target residue Mdm2 Tyr393 and the adjacent ATM 
target residue Mdm2 Ser394 are mutated (Mdm2Y393F/S394A).  Our study of these 
animals shows an apparent redundancy of the shared phenotypes between 
Mdm2Y393F and Mdm2S394A mice, with tumorigenesis and radioresistance in 
Mdm2Y393F/S394A mice never exceeding that observed in Mdm2S394A mice. 
 
Effects of Mdm2 phosphorylation on Mdm2 stability 
In Chapter II we show that Mdm2 is present at higher levels in the thymus 
and spleen of Mdm2S394A mice following DNA damage (Figures 2.1, 2.2, 2.5).  
Elevated Mdm2 levels are the result of Mdm2S394A being more stable following 
DNA damage (Figure 2.6).  Differences in Mdm2 expression do not appear to 
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influence the observed Mdm2 protein levels, as Mdm2 transcript levels are 
equivalent or even slightly reduced in both untreated and IR-treated Mdm2S394A 
thymi during this timeframe (Figure 2.3).  This result provides direct, in vivo 
evidence that DNA damage-induced phosphorylation of Mdm2 at this single 
residue by ATM induces Mdm2 destabilization.  Our results trend with previous in 
vitro studies that report a decrease in the half-life of Mdm2 after genotoxic stress 
(Stommel and Wahl, 2004; Itahana et al., 2007; Inuzuka et al. 2010).  
Furthermore, DNA damage-induced Mdm2 destabilization has been shown to be 
inhibited with the PIKK inhibitor wortmannin (Stommel and Wahl, 2004), and the 
analogous mutation of Ser395 in human Mdm2 has been shown to stabilize 
Mdm2 following DNA damage in transfection based assays (Stommel and Wahl, 
2004, Lu et al., 2007).   
The observed difference in the stability of phosphorylated Mdm2S394A after 
DNA damage differs from what our lab has previously reported (Gannon et al., 
2012).  It is possible that this new finding is the result of our using different, 
better-validated Mdm2 antibodies.  Our data also show that Mdm2 levels are 
elevated in thymi and spleens of Mdm2S394A mice in the absence of acute, 
exogenous DNA damage (Figures 2.1, 2.2, 2.6), again departing from our lab’s 
previous observations.  We interpret this finding to be indicative of some basal 
level of ATM activity in unstressed tissues that exerts influence on Mdm2 protein 
stability.   
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It is presently unclear how Mdm2 phosphorylation facilitates Mdm2 
destabilization.  One study has suggested that Mdm2 stability is primarily 
mediated through self-ubiquitination (Stommel and Wahl, 2004).  This study 
reached this conclusion by overexpressing an Mdm2 mutant with abrogated 
RING E3 activity (Mdm2C464A) in U2OS cells and observing little Mdm2 
destabilization following DNA damage.  This led the authors of the study to 
speculate as to a possible DNA damage-induced switch between Mdm2-
mediated degradation of p53 and itself.  However, a subsequent study in which 
MEFs from the corresponding Mdm2C462A knock-in mice were examined showed 
that Mdm2 RING E3 activity was in fact dispensable for Mdm2 destabilization 
after IR (Itahana et al., 2007).  These divergent results may be due to the 
differences in methodologies, and further emphasize the potential for disparities 
between transfection based studies and more endogenous conditions.		 
Degradation of Mdm2 in the absence of Mdm2 ubiquitin ligase function is 
indicative of other ubiquitin ligases being capable of regulating Mdm2 stability.  
One study has shown that the p300/CBP-associated factor (PCAF) is capable of 
promoting Mdm2 ubiquitination, and that PCAF can impact Mdm2 levels under 
unstressed conditions as well as Mdm2 destabilization in response to DNA 
damage (Linares et al., 2007).  Similarly, the anaphase-promoting 
complex/cyclosome (APC/C) E3 ubiquitin ligase complex has been shown to 
ubiquitinate Mdm2, with siRNA-mediated depletion of APC2, the Mdm2-binding 
member of the APC/C complex, leading to Mdm2 accumulation and diminished 
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p53 stabilization in response to DNA damage (He et al., 2014).  Other studies 
have identified the F-box proteins b-TRCP and FBXO31 as mediators of Mdm2 
degradation by the SCF complex (Inuzuka et al. 2010; Malonia et al., 2015).  b-
TRCP mediated degradation of Mdm2 is dependent on Mdm2 phosphorylation by 
CK1 and promotes Mdm2 turnover in response to DNA damage (Inuzuka et al. 
2010).  This is seemingly in contradiction with previous studies showing hypo-
phosphorylation of CK1 target residues on Mdm2 following DNA damage 
(Blattner et al., 2002).  Notably, knockdown of b-TRCP does not appear to impact 
the initial DNA damage-induced stabilization of p53, but rather Mdm2 stability 
and p53 levels at later time points in the damage response (Inuzuka et al. 2010).  
It has subsequently been shown that ATM phosphorylates CK1, and that this 
promotes CK1 nuclear localization and Mdm2 degradation (Wang et al., 2012).  It 
is conceivable that the phosphorylation state of Mdm2 at CK1 target residues has 
opposing effects on Mdm2 stability depending on the damage response phase 
and differing active signaling events.  Contrastingly, FBXO31 knockdown in cell 
lines abolishes the initial Mdm2 destabilization and p53 stabilization following 
DNA damage (Malonia et al., 2015).  FBXO31 can direct the polyubiquitination 
and degradation of Mdm2, and the FBXO31-Mdm2 interaction appears 
dependent on ATM phosphorylation of Mdm2 (Malonia et al., 2015).  However, 
the requirement for ATM phosphorylation was determined through the expression 
of an Mdm2 protein lacking all 6 proposed ATM target residues, and conversely, 
the treatment of lysates with phosphatase or cells with an ATM kinase inhibitor.  
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Consequently, the precise mechanism of how ATM phosphorylation of Mdm2 
Ser394 specifically promotes Mdm2 degradation under endogenous conditions 
remains to be determined. 
The methods and results described in Chapter II provide a starting point 
from which to further examine the mechanism of Mdm2 destabilization following 
Mdm2 Ser394 phosphorylation under endogenous conditions.  Preliminary co-
immunoprecipitation experiments have not proven successful for examining 
Mdm2-FBXO31 interactions in whole tissues.  However, further optimization of 
methods may allow for the examination of the impact of Mdm2 Ser394 
phosphorylation on Mdm2 interaction with the different ubiquitinating complexes 
listed above.  
In opposition to Mdm2 destabilization, a number of different mechanisms 
are proposed to promote Mdm2 stability.  These mechanisms include 
modifications of Mdm2 with the small, ubiquitin-like proteins SUMO (Small 
ubiquitin-related modifier) and NEDD8 (Neural precursor cell expressed 
developmentally down-regulated protein 8), which are separately proposed to 
have Mdm2 stabilizing effects and to decrease in response to DNA damage 
(Buschmann et al., 2001; Watson et al., 2010).  Additionally, Mdm2, MdmX and 
p53 can be deubiquitinated by the HAUSP (herpesvirus-associated ubiquitin-
specific protease) protein (Li et al., 2002a; Li et al., 2004; Meulmeester et al., 
2005).  DNA damage has been shown to reduce the affinity of Mdm2 and MdmX 
for HAUSP, leading to their enhanced ubiquitination (Meulmeester et al., 2005).  
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A proposed mechanism for the dissociation of Mdm2 from HAUSP involves ATM 
phosphorylation of Daxx (death domain-associated protein 6) triggering its 
dissociation from Mdm2, and relieving Daxx mediated promotion of Mdm2-
HAUSP interaction (Tang et al., 2006; Tang et al., 2013).  MDM2 is also been 
reported to be deubiquitinated by the ubiquitin-specific proteases USP2a and 
USP15 (Stevenson et al., 2007; Zou et al., 2014).  Notably, USP2a also acts as a 
deubiquitinating enzyme for MdmX, and is downregulated in response to cisplatin 
(Allende-Vega et al., 2010).  Accordingly, determining whether the interaction of 
Mdm2 with any of its proposed stabilizing interactors is affected in Mdm2S394A 
tissues or cells may also shed light on the destabilizing effect of Mdm2 Ser394 
phosphorylation.   
In Chapter III, in contrast to what was observed in Mdm2S394A tissues, we 
observed no differences in the levels of Mdm2 protein in Mdm2Y393F spleens or 
thymi following DNA damage (Figure 3.10).  However, we did observe slightly 
higher basal Mdm2 levels in Mdm2Y393F thymi.  It is possible that although 
ionizing radiation has been shown to activate c-Abl, its activation is not relevant 
in the response to IR in the tissues examined.  It is also possible that the 
additional proposed c-Abl targets (Tyr276 and Tyr405) are able to compensate 
for the absence of Mdm2 Tyr393 phosphorylation, at least in the acute response 
to DNA damage.  Notably, Mdm2 levels are similarly elevated and display 
qualitatively similar degradation kinetics after IR in Mdm2Y393F/S394A thymi as in 
Mdm2S394A thymi (Figure 3.31).  This follows with the lack of a contribution from 
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Mdm2 Tyr393 phosphorylation to Mdm2 destabilization after IR, and shows that it 
has no additive effects in conjunction with Mdm2 Ser394 phosphorylation.  One 
caveat of our results is that we have not been able to successfully detect c-Abl 
activation following stress.  Similarly, we have not been able to detect Mdm2 
Tyr393 phosphorylation in wild-type tissues.  We have been unsuccessful in 
detecting c-Abl activation by western blotting with antibodies specific for 
phosphorylated c-Abl (indicative of its activation), and no antibody is presently 
available that specifically detects Mdm2 phosphorylated at Tyr393.  Additional 
experiments to confirm these events in the tissues examined would be useful.  
Immunoprecipitation of c-Abl followed by an in vitro kinase assay may be 
required to detect its activation.  Similarly, immunoprecipitating Mdm2 and 
immunoblotting with an anti-phosphotyrosine antibody, or the reciprocal 
experiment, may allow for specific detection of Mdm2 tyrosine phosphorylation, 
and allow for a visualization of its reduction in Mdm2Y393F tissues.  As there is 
similarly no commercially available antibody that detects Mdm2 Ser394 
phosphorylation in mouse tissues, this approach may also work for detection of 
Mdm2 Ser394 phosphorylation using an anti-phosphoserine antibody.  
Alternatively, the phosphorylation state of Mdm2 Tyr393 and Mdm2 Ser394 could 
be examined by mass spectrometry. 
The proximity of Mdm2 Tyr393 and Mdm2 Ser394 raises the possibility 
that mutation of either residue may be interfering with the phosphorylation of the 
other, or impacting the recognition and dephosphorylation of the neighboring 
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residue by the relevant phosphatase.  This could theoretically result in either 
mutation acting to promote a hypomorphic or hypermorphic effect at the 
neighboring residue, potentially muddling the phenotypes (or lack thereof) 
observed for either mutation.  As such, it would be interesting to use the above 
proposed techniques to examine the phosphorylation status of the neighboring 
residue as well, in DNA damaged Mdm2Y393F and Mdm2S394A tissues.  
Furthermore, as Mdm2 Ser394 is known to be dephosphorylated by the Wip1 
phosphatase (Lu et al., 2007), the interaction of Wip1 with Mdm2Y393F could be 
examined. 
While we have shown that Mdm2 Ser394 phosphorylation governs Mdm2 
destabilization in response to ionizing radiation in vivo, and similar observations 
have been made in cell culture settings using IR and the radiomimetic 
neocarzinostatin (NCS) (Stommel and Wahl, 2004; Lu et al., 2007), another 
study has observed no effect of phosphorylation of this residue on Mdm2 
destabilization in response to the topoisomerase inhibitor etoposide (Wang et al., 
2012).  Therefore, different DNA damaging agents may display differing levels of 
reliance on the phosphorylation of specific Mdm2 residues for the destabilization 
of Mdm2 and activation of p53.  Further studies of the effects on Mdm2 stability 
and p53 activation in Mdm2Y393F, Mdm2S394A and Mdm2Y393F/S394A mice or cells 
treated with an array of DNA damaging agents may identify specific damage 
responses with distinct or overlapping requirements for phosphorylation of either 
Mdm2 Tyr393 or Ser394. 
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Effects of Mdm2 phosphorylation on p53 stabilization and activation  
In Chapter II, the increased levels of Mdm2 observed in the thymus and 
spleen of Mdm2S394A mice after DNA damage correlate with a decrease in p53 
levels, p53 target gene expression and apoptosis in these tissues (Figures 2.1-
2.5).  Previous studies have suggested that ATM phosphorylation of the 
analogous residue on human MDM2 (Ser395), either alone or in combination 
with several other ATM-target serine residues in the same region, impacts the 
ability of Mdm2 to promote p53 degradation and nuclear export, and governs 
Mdm2 RING-domain oligomerization and polyubiquitination of p53 (Maya et al., 
2001; Cheng et al., 2009).  DNA damage resulted in p53 stabilization in WT 
thymocytes, albeit after a brief period of p53 degradation (Figure 2.9).  While the 
initial rate of p53 degradation does not appear affected in irradiated Mdm2S394A 
thymocytes, we observed a prolonged period of p53 destabilization, ultimately 
resulting in lower relative levels of p53.  This prolonged, rather than accelerated, 
p53 destabilization aligns more with the increased stability of Mdm2S394A after 
DNA damage leading to increased Mdm2-bound p53 than with altered Mdm2 
ubiquitination activity.  This is supported by the increased relative amounts of 
Mdm2-bound p53 after IR observed in Mdm2S394A thymi (Figure 2.10).  However, 
an effect on Mdm2 ubiquitination activity cannot be ruled out, as the differing 
levels of Mdm2 and p53, and different rates of Mdm2 degradation in wild-type 
and Mdm2S394A thymi preclude the accurate quantitation of relative p53 
ubiquitination by Mdm2 in vivo.  
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It is likely that DNA damage-induced p53 activity is caused not only by 
reduced Mdm2-mediated p53 degradation (due to destabilization of Mdm2) but 
also by reduced Mdm2 steric inhibition of p53.  As Mdm2 binds to the amino-
terminal, transcriptional activation domain of p53 and inhibits p53 target gene 
expression, reduced Mdm2-p53 complex formation after Mdm2 phosphorylation 
by ATM may account for an increase in p53 activity even when p53 protein 
stability is only modestly altered (Momand et al., 1992; Oliner et al., 1993).  
Though visibly reduced in comparison to WT tissues, we still see moderate to 
significant levels of p53 stabilization in both Mdm2S394A thymus and spleen 
(Figures 2.1 and 2.5).  The greater relative differences in p53 target gene 
expression and protein levels in Mdm2S394A tissues suggests further regulation of 
p53 activity beyond its stabilization (Figures 2.1, 2.3, 2.5).  This is also supported 
by the increased relative amounts of Mdm2-bound p53 after IR observed in 
Mdm2S394A thymi (Figure 2.10).  As described above regarding the cause of 
decreased p53 stabilization in Mdm2S394A tissues, definitively distinguishing 
whether increased Mdm2-p53 binding in Mdm2S394A tissues is due to increased 
Mdm2S394A levels, or a reduced affinity of phosphorylated Mdm2 for p53 would 
likely require moving to more controlled in vitro experiments.     
In Chapter III, mirroring the absence of detectible differences in Mdm2 
destabilization following IR, we observed no differences in p53 stabilization and 
p53 target gene expression in spleens and thymi of Mdm2Y393F mice (Figures 
3.10 and 3.11).  Accordingly, no differences were detected in splenic or thymic 
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apoptosis in irradiated Mdm2Y393F mice, or growth arrest in MEFs treated with IR 
or doxorubicin (Figures 3.12-3.14).  As with IR-induced destabilization of Mdm2, 
no additive effects were observed in Mdm2Y393F/S394A mice relative to Mdm2S394A 
mice in the reduction of p53 stabilization and activity following IR (Figures 3.31-
3.34).  Again, additional studies employing different DNA damaging agents may 
expose unidentified damage-specific defects in p53 responses in Mdm2Y393F 
mice. 
 
Mdm2 phosphorylation in spontaneous tumor suppression 
 Our lab had previously published that Mdm2S394A mice are prone to 
spontaneous tumors (Gannon et al., 2012).  In Chapter III we report that 
Mdm2Y393F mice are viable and display no developmental defects, yet they are 
significantly more prone to developing spontaneous tumors over their lifespan 
(Figure 3.6).  The Mdm2Y393F tumor spectrum, as well as latency, largely mirrors 
those observed with both p53+/  and Mdm2-transgenic mice, with a large 
percentage of B cell lymphomas (Table 3.1, Figures 3.7 and 3.8) (Jones et al., 
1998; Wang et al., 2008; Donehower and Lozano, 2009).  We observed no 
synergistic effects of the loss of both Mdm2 Tyr393 and Ser394 phosphorylation 
on the incidence of spontaneous tumorigenesis.  Mdm2Y393F/S394A mice developed 
spontaneous tumors at a frequency and latency that nearly overlap what we have 
reported with Mdm2S394A mice (Figure 3.28).  Again the tumor spectrum, as well 
as latency, largely mirrors those observed with p53+/  and Mdm2-transgenic mice, 
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with a large percentage of B cell lymphomas as well as sarcomas (Table 3.1, 
Figures 3.7 and 3.8).  Thus, c-Abl phosphorylation of Mdm2 Tyr393 significantly 
impacts spontaneous tumor suppression, though to a lesser extent than Mdm2 
Ser394 phosphorylation, and in an apparently redundant manner.  This may 
reflect the proposed interdependence of c-Abl and ATM for their respective 
activities in response to DNA damage (Baskaran et al., 1997; Shafman et al., 
1997; Wang et al., 2011a).    
We infer that the observed increases in spontaneous tumorigenesis in 
Mdm2Y393F, Mdm2S394A and Mdm2Y393F/S394A mice are the result of reduced p53-
dependent functions.  However, it is possible that the elevated basal Mdm2 
protein levels observed in Mdm2S394A and Mdm2Y393F/S394A mice exert p53-
independent oncogenic effects.  A p53-independent oncogenic function of Mdm2 
was first inferred from the altered tumor spectrum of p53 /  mice expressing an 
Mdm2 transgene (Jones et al., 1998).  It was later shown that overexpression of 
Mdm2 inhibits DNA double-strand break repair independent of p53 and possibly 
through its interaction with Nbs1 (Alt et al., 2005), and B cells from Mdm2-
transgenic mice display an increased frequency of chromosomal/chromatid 
breaks and/or aneuploidy (Wang et al., 2008).  It would be interesting to generate 
Mdm2S394A and Mdm2Y393F/S394A mice on a p53 /  background to examine whether 
the observed tumor suppressive effects of Mdm2 phosphorylation are dependent 
on p53.  Relatedly, metaphases from splenocytes or purified B cells from these 
animals could be examined for differences in chromosomal stability.  This same 
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approach could also be used to explore the p53-dependence of the reduced 
tumor suppression in response to activated Myc observed in Mdm2S394A and 
Mdm2Y393F mice (discussed below). 
 
Mdm2 phosphorylation in Myc-driven tumorigenesis 
The reduced level of p53 activity in Mdm2S394A mice likely facilitates the 
more rapid Eμ-myc-driven B cell lymphomagenesis described in Chapter II 
(Figure 2.12).  Both p53-dependent apoptosis and senescence have been shown 
to inhibit B-cell lymphomagenesis induced by aberrant Myc activity (Eischen et 
al., 1999; Eischen et al., 2001; Schmitt et al., 2002; Post et al., 2010).  It has 
been previously demonstrated that activated oncogenes such as Myc result in 
elevated Arf expression, a result of hyperproliferative signaling (Zindy et al., 
1998; Sherr et al., 2005).  The importance of disrupting the Arf-Mdm2-p53 
pathway in Myc-driven lymphomagenesis is evidenced by the fact that Eμ-myc 
driven tumors in mice face a selective pressure to inactivate the p53 pathway, by 
either p53 mutation, Mdm2 overexpression, or loss of Arf (Eischen et al., 1999).  
However, we observed a significant acceleration in the median time of tumor 
presentation in Eμ-myc;Mdm2S394A mice in the absence of Mdm2 overexpression 
or p53 mutation in tumors (Figure 2.14).  This suggests that the absence of 
Mdm2 Ser394 phosphorylation is sufficient to diminish p53 activity in response to 
oncogene activation and reduces the selective pressure to genetically disrupt the 
Mdm2-p53 signaling axis (Figure 2.15).  Although loss of Arf was observed in a 
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subset of Eμ-myc;Mdm2S394A tumors, this finding likely reflects the ability of Arf to 
prevent tumorigenesis in Eμ-myc mice through an Mdm2-p53 independent 
mechanism.  
As Mdm2S394A mice are deficient for an acute DNA damage-associated 
phosphorylation event, it is tempting to view the acceleration of 
lymphomagenesis in Eμ-myc;Mdm2S394A mice as tied to the acute DNA damage 
response (Figure 2.15).  However, Mdm2 protein levels are elevated in spleens 
of Mdm2S394A mice in the absence of acute DNA damage (Figure 2.5) and Mdm2-
transgenic mice have been shown to develop accelerated Eμ-myc-driven 
lymphomas displaying reduced selection for p53 inactivation (Wang et al., 2008).  
It cannot be ruled out that the accelerated lymphomagenesis observed in Eμ-
myc;Mdm2S394A mice is due to elevated Mdm2 levels resulting from impaired 
basal levels of Ser394 phosphorylation, and not the impaired acute DNA damage 
response of Mdm2S394A mice. 
In Chapter III we report similarly accelerated B cell lymphomagenesis in 
Eμ-myc;Mdm2Y393F mice as in Eμ-myc;Mdm2S394A mice (Figure 3.9).  As 
discussed above, we have observed no defects in p53-dependant apoptosis or 
growth arrest in Mdm2Y393F tissues and cells following DNA damage (Figures 
3.12-3.14).  It is conceivable that Mdm2 phosphorylation by c-Abl regulates p53 
tumor suppressive functions other than apoptosis or growth arrest, or that that 
subtle differences in p53 functions, not detectable by acute damage in Mdm2Y393F 
mice, have a cumulative effect on p53 tumor suppression.  Unlike Mdm2S394A 
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mice, we have not observed significantly elevated basal levels of Mdm2 protein 
in Mdm2Y393F spleens.   
It would be informative to examine the status of the Arf-Mdm2-p53 
pathway in Eμ-myc;Mdm2Y393F tumors.  If Eμ-myc;Mdm2Y393F tumors similarly do 
not select for alterations in the Arf-Mdm2-p53 pathway, as was observed with Eμ-
myc;Mdm2S394A mice, it would support that the absence of Mdm2 Tyr393 
phosphorylation leads to a deficiency in p53 function.  Also, crossing 
Mdm2Y393F/S394A mice with Eμ-myc mice would allow us to explore whether the 
accelerated lymphomagenesis in Eμ-myc;Mdm2Y393F mice and Eμ-
myc;Mdm2S394A mice is occurring through similar pathways, and whether 
phosphorylation of Mdm2 Tyr393 and Ser394 have additive or redundant effects 
in suppressing oncogene-induced tumorigenesis.   
It would also be interesting to examine Arf, Mdm2 and p53 protein levels 
in pre-neoplastic spleens or bone marrow, or cultured pre-B cells, from Eμ-myc, 
Eμ-myc;Mdm2Y393F and Eμ-myc;Mdm2S394A mice.  Arf and p53 levels are 
elevated in pre-B cells in pre-neoplastic Eμ-myc mice (Eischen et al., 1999).  
Observing reduced levels of p53 in Eμ-myc;Mdm2Y393F and/or Eμ-myc;Mdm2S394A 
samples would support the p53-dependence of the observed accelerations in 
lymphomagenesis.  This would also show whether the stress caused by activated 
oncogenes has any effect on Mdm2Y393F or Mdm2S394A protein levels.  Relatedly, 
it would be interesting to determine whether any differences in apoptosis or 
senescence are detectible in these same tissues or cells.   
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Mdm2 phosphorylation in IR-induced lymphomagenesis and 
radioresistance 
In Chapter II, to further explore a role for Mdm2 Ser394 phosphorylation in 
the DDR and in regulation of p53 tumor suppression, we examined 
lymphomagenesis induced by low level exposure of mice to ionizing radiation 
(Figures 2.16-2.18).  In contrast to Myc-driven lymphomagenesis, Mdm2S394A 
mice proved to be resistant to DNA damage-induced T cell lymphomagenesis, 
highlighting a stark difference in the effects of ATM-Mdm2-p53 signaling on 
lymphomas induced by different types of DNA damage-related stress.  
The cell of origin in IR-induced lymphomas has historically been viewed as 
a stem/progenitor cell residing within the bone marrow (Kaplan, 1964), and IR-
induced lymphomagenesis is significantly enhanced in the absence of functional 
p53 (Kemp et al., 1994).  Subsequent studies examining the contribution of the 
p53-dependent pro-apoptotic genes Puma and Noxa made the paradoxical 
observation that Puma /  mice develop fewer IR-induced lymphomas (Labi et al., 
2010; Michalak et al., 2010).  This was attributed to increased survival of 
leukocytes in the bone marrow, which reduced the proliferative stress and/or 
propagation of lesions within progenitor cells tasked with repopulating the bone 
marrow.  That Noxa /  mice displayed only modest radioprotection of L−SK cells 
and developed more lymphomas was interpreted as a failure to clear damaged 
progenitors, thereby promoting the survival of damaged stem/progenitor cells 
(Michalak et al., 2010).  Despite a reduction of p53-dependent gene expression 
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of Puma and Noxa in total bone marrow of IR-damaged Mdm2S394 mice (Figure 
2.19), we observed no defects in the attrition of mature hematopoietic cells or 
lineage-defined progenitor cells (CMPs) (Figures 2.22 and 2.23).  Only the most 
primitive HSPCs display resistance to IR (Figure 2.23).  Our finding that 
Mdm2S394A mice are resistant to IR-induced lymphomas reveals that the effects 
of a reduced p53-dependent damage response in Mdm2S394A mice does not 
mirror the ablation of either Puma or Noxa alone.  Interestingly, a recent study by 
Kirsch and colleagues suggests that the tumor-initiating cell in IR-induced 
lymphomas is thymic in origin (Lee et al. 2015).  Using mice in which p53 activity 
was temporally blocked during total-body irradiation, the authors propose that the 
IR-induced p53 response in bone marrow promotes lymphomagenesis by 
reducing HSPC fitness, thereby reducing the competition of cells originating from 
the bone marrow with thymocytes containing oncogenic lesions.  The results we 
have observed with Mdm2S394A mice align favorably with this model, as we have 
observed less p53 activity and increased HSPC fitness in Mdm2S394A mice 
following threshold-lethal doses of radiation, and reduced incidence of T cell 
lymphomagenesis in Mdm2S394A mice after IR exposure.  The p53 dependence of 
the increased HSPC fitness in Mdm2S394A mice is further intimated by studies 
which have observed increased bone marrow repopulation potential in bone 
marrow deficient for p53, both in the presence and absence of IR (reviewed in 
Pant et al., 2012).  Interestingly, a recent study has linked Mdm2 to enhanced 
stem-ness via association with the Polycomb Repressor Complex 2 (PRC2) 
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(Wienken et al., 2015).  Further studies into the relative p53-dependent and p53-
independent contributions of Mdm2 to HSPC fitness are clearly warranted.  
In Chapter III, despite the absence of observable defects in p53 responses 
to DNA damage in Mdm2Y393F thymus, spleen or MEFs, we show that Mdm2Y393F 
mice are resistant to threshold-lethal doses of IR (Figure 3.16).  This 
radioresistance parallels our previous observations with Mdm2S394A mice, which 
display profound defects in p53-dependent apoptosis and growth arrest and 
tissues and cells.  HSPC or bone marrow cells from both mutants display 
improved repopulating functions following IR exposure, albeit to a lesser extent in 
Mdm2Y393F mice (Figure 3.22).  In keeping with this difference, HSPCs in 
Mdm2S394A bone marrow display a significant survival advantage following IR, 
whereas Mdm2Y393F HSPCs display only a marginal possible increase in survival 
after DNA damage (Figure 3.21).  
As with the acute p53 response to DNA damage and spontaneous 
tumorigenesis, we observed no additive effects on radioresistance when both 
Mdm2 Tyr393 and Ser394 were mutated.  Mdm2Y393F/S394A and Mdm2S394A mice 
displayed comparable survival, HSPC numbers, and bone marrow reconstitution 
following whole body IR (Figures 3.35-3.38).  Hence, there is an apparent 
redundancy of the shared phenotypes between Mdm2Y393F and Mdm2S394A mice, 
with tumorigenesis and radioresistance in Mdm2Y393F/S394A mice never exceeding 
that observed in Mdm2S394A mice.  However, ATM phosphorylation of Mdm2-
S394 clearly has a predominant effect on Mdm2-p53 signaling and p53 functions 
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relative to the effects induced by c-Abl phosphorylation of Mdm2 Tyr393. 
We infer that a very slight increase in the survival of Mdm2Y393F HSPCs 
may account for the increased bone marrow repopulation and radioresistance in 
Mdm2Y393F mice, as Mdm2Y393F/S394A and Mdm2S394A mice display further 
increased bone marrow repopulation and radioresistance along with significantly 
higher levels of HSPCs after IR.  However, it is possible that the improved 
repopulation in Mdm2Y393F mice is the result of increased cycling of surviving 
HSPCs, possibly reflecting a different stress (such as reactive oxygen species) 
that c-Abl phosphorylation of Mdm2 plays a greater role in the response to.  As 
such it would be interesting to perform cell cycle analysis on HSPCs from 
irradiated WT and Mdm2-mutant mice.  
 
General Conclusions 
 
This dissertation presents a number of findings that appreciably further our 
understanding of the significance of Mdm2 phosphorylation by DNA damage-
responsive kinases on p53 responses and tumor suppression in vivo.  We show 
that phosphorylation of different Mdm2 residues by kinases associated with the 
DNA damage response can profoundly impact Mdm2 stability, p53 stabilization 
and activation, and tumor suppression.  The effects that we observed in 
response to ATM phosphorylation of Mdm2 Ser394 and c-Abl phosphorylation of 
Mdm2 Tyr393 were both overlapping and distinct (Figure 4.1).   
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Figure 4.1.  Graphical summary of the effects of Mdm2 Tyr393 and Mdm2 
Ser394 phosphorylation on p53-dependent DNA damage responses and 
tumor suppression.   
 
 
Our findings indicate the potential for an additional layer of pharmaceutical 
control of the p53 pathway.  We have shown phosphorylation of Mdm2 Tyr393 
and Mdm2 Ser394 to significantly impact the capacity of HSPCs to repopulate 
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bone marrow following irradiation and (in the case of Ser394 phosphorylation) 
simultaneously protect against lymphomagenesis induced by repeated IR 
exposure.  While broad inhibition of DNA damage responsive kinases such as 
ATM and c-Abl would likely be undesirable due to their involvement in additional 
processes such as DNA repair, small-molecule therapeutics that inhibit DNA 
damage-induced Mdm2 phosphorylation events may be useful both in basic 
research and in the clinic.  In patients undergoing radiotherapy, acute p53-
dependent apoptosis in normal radiosensitive tissues is a major source of side 
effects. Transiently blocking DNA damage-induced Mdm2 phosphorylation may 
prove to be a useful manner of reducing unwanted side effects without 
compromising p53 tumor suppressive function. 
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